Page last updated: 2024-11-05

silybin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Silybin is a flavonolignan, a type of natural compound found in milk thistle (Silybum marianum). It is the most active component of the milk thistle extract silymarin. Silybin has been studied for its potential health benefits, including liver protection, anti-inflammatory, and antioxidant effects. It is thought to work by protecting liver cells from damage caused by toxins and oxidative stress. Silybin is also being investigated for its potential to treat various conditions, such as non-alcoholic fatty liver disease, viral hepatitis, and cancer. Silybin is synthesized naturally by the milk thistle plant. It is also available as a dietary supplement. While research on silybin is ongoing, it has shown promise as a potential therapeutic agent for a range of health conditions.'

silibinin : A flavonolignan isolated from milk thistle, Silybum marianum, that has been shown to exhibit antioxidant and antineoplastic activities. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Silybumgenus[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Silybumgenus[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Silybum marianumspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Silybumgenus[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID3086637
CHEMBL ID9509
SCHEMBL ID14270800
SCHEMBL ID22398934
MeSH IDM0019880
PubMed CID31553
CHEMBL ID431701
CHEBI ID9144
SCHEMBL ID324884
MeSH IDM0019880
PubMed CID124304713
MeSH IDM0019880

Synonyms (120)

Synonym
silibin
silybine
silliver
legalon
S0508
2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3,5,7-trihydroxy-4-oxobenzopyran-2-yl)benzodioxine
silibinin a-silibinin b mixt.
CHEMBL9509
(2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
SCHEMBL14270800
SCHEMBL22398934
E80721
CS-0138778
HY-N0779A
(2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydro-4h-chromen-4-one
BRD-K80353138-001-02-2
SDCCGMLS-0066916.P001
flavobin spofa
7c3mt
silymarin i
3,5,7-trihydroxy-2-(3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxan-6-yl)-4-chromanone
silibininum [inn-latin]
flavobin
einecs 245-302-5
nsc 651520
4h-1-benzopyran-4-one, 2-(2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-, (2r-(2alpha,3beta,6(2r*,3r*)))-
silibinina [inn-spanish]
silymarine i
silibinine [inn-french]
silibinin [inn]
4h-1-benzopyran-4-one, 2,3-dihydro-2-(2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-3,5,7-trihydroxy-, (2r-(2-alpha,3-beta,6(2r*,3r*)))-
nsc-651520
SPECTRUM4_001978
BSPBIO_002623
SPECTRUM5_001893
SMP2_000323
MEGXP0_001301
4h-1-benzopyran-4-one, 2-[(2r,3r)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-, (2r,3r)-
nsc651520
3,5,7-trihydroxy-2-(3-(4-hydroxy-3-methoxyphenyl)- 2-(hydroxymethyl)-1,4-benzodioxan-6-yl)-4-chromanone
(2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one
NCGC00091057-01
silibinin
22888-70-6
KBIOGR_002481
KBIO3_002123
SPBIO_001648
SPECTRUM2_001694
SPECTRUM3_001132
SPECTRUM1505256
NCGC00091057-02
smr000718776
MLS001304057
silybinin
silybin a
silibinin a
sr-01000799140
SR-01000799140-2
(2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxy-phenyl)-2-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-yl]-chroman-4-one
silymarine
bdbm50084982
3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxy-phenyl)-2-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-yl]-chroman-4-one
3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-hydroxymethyl-(2r,3r)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]-(2r,3r)-3,4-dihydro-2h-4-chromenone
(2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxy-phenyl)-2-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-yl]-chroman-4-one
(2r,3r)-3,5,7-trihydroxy-2-((2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)chroman-4-one
silibinin (inn)
legalon (tn)
D08515
HMS1922P05
(2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
AKOS004119918
NCGC00091057-03
tox21_200755
NCGC00258309-01
cas-22888-70-6
dtxsid8026018 ,
dtxcid106018
tox21_111070
HMS2232P03
chebi:9144 ,
CHEMBL431701
CCG-38779
unii-33x338mne4
ccris 9378
silibinina
silibininum
silibinine
33x338mne4 ,
S2357
1265089-69-7
BP-30210
HY-13748
SCHEMBL324884
SEBFKMXJBCUCAI-HKTJVKLFSA-N
tox21_111070_1
NCGC00091057-05
4h-1-benzopyran-4-one, 2-((2r,3r)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-, (2r,3r)-
silybin a [mi]
silybin a (constituent of milk thistle) [dsc]
mfcd00872186
Q-100291
AB00876265_06
silybin a (constituent of milk thistle)
(2r,3r)-3,5,7-trihydroxy-2-(3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)chroman-4-one
DB09298
SBI-0207018.P001
(2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2h-1-benzopyran-4-one
DS-9661
Q425702
silibinin (silybin)
BRD-K80353138-001-07-1
AMY28808
silybin;silibinin a;silymarin i
methanone, cyclohexyl-1-pyrrolidinyl-
4h-1-benzopyran-4-one,2-[(2r,3r)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-, (2r,3r)-
E82516
( inverted exclamation marka)-silybin
CS-0226432
gtpl12449
silybin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" To ensure a safe and effective product, botanical dietary supplements should be developed in a manner analogous to pharmaceuticals that involves identification of mechanisms of action and active constituents, chemical standardization based on the active compounds, biological standardization based on pharmacological activity, preclinical evaluation of toxicity and potential for drug-botanical interactions, metabolism of active compounds, and finally, clinical studies of safety and efficacy."( Development of Safe and Effective Botanical Dietary Supplements.
van Breemen, RB, 2015
)
0.42
"Acetaminophen, a safe analgesic when dosed properly but hepatotoxic at overdoses, has been reported to induce DNA strand breaks but it is unclear whether this event preceeds hepatocyte toxicity or is only obvious in case of overt cytotoxicity."( Antioxidants protect primary rat hepatocyte cultures against acetaminophen-induced DNA strand breaks but not against acetaminophen-induced cytotoxicity.
El-Bahay, C; Hanelt, S; Kahl, R; Lewerenz, V; Nastevska, C; Röhrdanz, E, 2003
)
0.32
" Furthermore, the use of antidotes that reduced the toxic insult was also recorded using this technique."( Acute liver acetaminophen toxicity in rabbits and the use of antidotes: a metabonomic approach in serum.
Galanopoulou, P; Giannioti, K; Liapi, C; Mikros, E; Papalois, A; Theocharis, S; Zira, A, 2009
)
0.35
" Administration of studied antidotes without alpha-AMA, was not associated with any adverse effects in hepatocytes."( Failure of benzylpenicillin, N-acetylcysteine and silibinin to reduce alpha-amanitin hepatotoxicity.
Dziegiel, P; Izykowska, I; Magdalan, J; Nowak, M; Ostrowska, A; Piotrowska, A; Szelag, A,
)
0.13
" According to the detected ethanol toxic response marked by reduced cell viability, 3D cultured hepatocytes in gel entrapment were suggested to be better than 2D hepatocyte in monolayer, but the cultures in either William's Medium E or DMEM exhibited comparable sensitivity to ethanol toxicity."( Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.
Meng, Q; Ruan, X; Shen, C, 2010
)
0.36
" Short-term intravenous silibinin monotherapy is safe and shows a potent in vivo anti-HCV effect."( Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.
Albillos, A; Arocena, C; Bárcena, R; Bermejo, T; Blesa, C; Del Campo, S; Gajate, L; García-Hoz, F; Graus, J; López-Hervás, P; Martínez, A; Mateos, ML; Moreno, A; Nuño, J; Rodríguez-Gandía, MA, 2013
)
0.39
"Prolonged intravenous silibinin monotherapy was safe in the immediate liver transplantation period, leading to a potent and time dependent antiviral effect and lack of HCV-RNA breakthrough during administration."( Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.
Albillos, A; Arocena, C; Bárcena, R; Bermejo, T; Blesa, C; Del Campo, S; Gajate, L; García-Hoz, F; Graus, J; López-Hervás, P; Martínez, A; Mateos, ML; Moreno, A; Nuño, J; Rodríguez-Gandía, MA, 2013
)
0.39
" The beverages were well-tolerated with no adverse effects."( Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.
Šimánek, V; Stuchlík, M; Ulrichová, J; Vacek, J; Valentová, K; Vidlář, A; Zatloukalová, M, 2013
)
0.39
" As transplant community identified HCV viral clearance as a critical matter, efficacious and safe anti-HCV therapies are awaited."( Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
Brambilla, N; Bringiotti, RS; Castellaneta, A; Castellaneta, NM; D'Amato, M; Di Leo, A; Giacovelli, G; Rendina, M; Rizzi, SF; Rovati, L; Zappimbulso, M, 2014
)
0.4
" In this project, we evaluated the effects of silibinin, a natural plant component of milk thistle seeds, to potentiate toxic effects of chemotherapy drugs such as temozolomide, etoposide and irinotecan on LN229, U87 and A172 (P53 and phosphatase and tensin homolog (PTEN) -tumor suppressor-mutated) glioma cell lines."( The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Elhag, R; Mazzio, EA; Soliman, KF, 2015
)
0.42
" Our earlier report has demonstrated the therapeutic efficacy of silibinin, a natural flavanone, in reversing monofunctional alkylating SM analog 2-chloroethyl ethyl sulfide-induced toxic effects in mouse skin."( Flavanone silibinin treatment attenuates nitrogen mustard-induced toxic effects in mouse skin.
Agarwal, C; Agarwal, R; Inturi, S; Jain, AK; Kumar, D; Orlicky, DJ; Tewari-Singh, N; White, CW, 2015
)
0.42
"Mounting evidence suggests that long-term aluminum exposure results in severe toxic effects, including neurobehavioral and neurochemical anomalies."( Hesperidin and Silibinin Ameliorate Aluminum-Induced Neurotoxicity: Modulation of Antioxidants and Inflammatory Cytokines Level in Mice Hippocampus.
Bezbaruah, BK; Dwivedi, S; Gogoi, R; Gurjar, SS; Jangra, A; Kasbe, P; Kwatra, M; Lahkar, M; Mishra, M; Pandey, SN; Sarma, N; Sulakhiya, K; Venu, AK, 2015
)
0.42
"The present study was designed to evaluate the hepatoprotective and antioxidant potentials of silibinin (SBN) against N-nitrosodimethylamine (DMN)-induced toxic insults in the rat liver."( Silibinin alleviates N-nitrosodimethylamine-induced glutathione dysregulation and hepatotoxicity in rats.
Ezhilarasan, D; Karthikeyan, S, 2016
)
0.43
" This study investigate the hepatotoxic potentials of AZT alone, INH alone and AZT+INH treatments and the mitigating potentials of SBN against these drugs induced toxic insults of liver in rats."( Zidovudine and isoniazid induced liver toxicity and oxidative stress: Evaluation of mitigating properties of silibinin.
Karthikeyan, S; Raghu, R, 2016
)
0.43
" Niosomes are biodegradable, biocompatible, safe and effective carriers for drug delivery."( Preparation, Characterization and Cytotoxicity of Silibinin- Containing Nanoniosomes in T47D Human Breast Carcinoma Cells.
Akbarzadeh, A; Amiri, B; Chiani, M; Ebrahimi-Far, M; Saffari, Z; Soleimani, E, 2016
)
0.43
" Silibinin caused clear-cut protective effects, but with few parameters INH toxicity was even aggravated, most probably due to increased metabolization of INH into its toxic metabolite."( Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.
Decker, M; Lupp, A; Mann, A; Mosig, A; Pelz, T; Rennert, K, 2017
)
0.46
" The present study evaluates the ameliorative effect of SBN against AZT alone, INH alone, and INH + AZT-induced toxic insults to liver of rats."( Evaluation of ameliorative ability of Silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats: Role of Silibinin in Phase I and II drug metabolism.
Ramanathan, R; Sivanesan, K, 2017
)
0.46
" The efficacy of paclitaxel, a frequently used GC chemotherapeutic agent, is hindered due to drug resistance, dose‑induced toxicity and adverse side effects."( Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines.
Ge, Y; Lou, D; Ping, X; Shi, W; Yu, M; Zhang, Y, 2018
)
0.48
" Here we employ in vitro, biophysical, and computational methods to inspect the ability of Silybin A and Silybin B, two natural diastereoisomers extracted from milk thistle, to interfere with the toxic self-assembly of human IAPP (hIAPP)."( Silybins inhibit human IAPP amyloid growth and toxicity through stereospecific interactions.
Caflisch, A; Di Fabio, G; García-Viñuales, S; Ilie, IM; Milardi, D; Romanucci, V; Santoro, AM; Zarrelli, A, 2022
)
0.72
" Abrin is considerably more toxic than ricin and a potent bio-warfare agent."( Silibinin ameliorates abrin induced hepatotoxicity by attenuating oxidative stress, inflammation and inhibiting Fas pathway.
Dhaked, RK; Nagar, DP; Saxena, N, 2022
)
0.72

Pharmacokinetics

The aim of the present study was to find a way of prepare silybin-phospholipid complex to make oral bioavailability of sily bin increase. The study also aimed to study its physicochemical properties and to compare the pharmacokinetic characteristics and bioavailability after oral administration of slybin-N-methylglucamine in rats.

ExcerptReferenceRelevance
"The aim of the present study was to find a way of prepare silybin-phospholipid complex to make oral bioavailability of silybin increase and to study its physicochemical properties and to compare the pharmacokinetic characteristics and bioavailability after oral administration of silybin-phospholipid complex and silybin-N-methylglucamine in rats."( The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
Qineng, P; Yanyu, X; Yunmei, S; Zhipeng, C, 2006
)
0.33
"To develop a new HPLC-UV method of determining silybin in human plasma and to study the pharmacokinetic of silybin-phosphatidylcholine complex (silybinin capsules) in healthy male Chinese volunteers using the new developed method."( Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers.
Gao, J; Li, W; Liu, CX; Zhao, HZ,
)
0.13
"To evaluate the pharmacokinetic interaction between oltipraz and silymarin after intravenous and oral administration of both drugs to male Sprague-Dawley rats."( Pharmacokinetic interaction between oltipraz and silymarin in rats.
Bae, SK; Kang, MK; Kim, JW; Lee, MG, 2009
)
0.35
"The pharmacokinetic parameters of oltipraz did not significantly altered by silymarin."( Pharmacokinetic interaction between oltipraz and silymarin in rats.
Bae, SK; Kang, MK; Kim, JW; Lee, MG, 2009
)
0.35
"0g/kg silymarin significantly decreases trazodone's area under concentration curve (AUC), distribution half-life (t(1/2,alpha)), elimination half-life (t(1/2,beta)), and mean residence time (MRT)."( Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats.
Chang, JC; Lee, WC; Lin, LC; Tsai, TH; Wu, YT, 2009
)
0.35
" The pharmacokinetic parameters of paclitaxel were determined in rats after oral (40 mg/kg) or intravenous (4 mg/kg) administration in the presence and absence of silibinin (0."( Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Choi, JS; Lee, CK, 2010
)
0.36
" Additionally, the steady-state pharmacokinetic parameters were determined after the subjects were administered one capsule three times daily for 28 consecutive days."( An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
Bernstein, HJ; Brinda, BJ; Chavin, KD; Markowitz, JS; Patrick, KS; Zhu, HJ, 2013
)
0.39
" The plasma concentration of nitrendipine was estimated by high performance liquid chromatography and different pharmacokinetic parameters were calculated using WinNonlin(®) software."( Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits.
Voruganti, S; Yamsani, MR; Yamsani, SK, 2014
)
0.4
" The present study was to investigate the effects of giving N-acetylcysteine (NAC) alone and in combination with either glycyrrhizin (GL), silibinin (SIB) or spironolactone (SL) on the plasma pharmacokinetic (PK) profiles, hepatic exposure, biliary excretion and urinary excretion of acetaminophen (APAP) and its major metabolite, acetaminophen glucuronide (AG)."( Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat.
Liu, X; Wang, Q; Xu, R; Yang, J; Zang, M; Zhang, J, 2014
)
0.4
" Pharmacokinetic behaviors of silybin in rats were altered by co-administration of tangeretin, in terms of increased AUC and Cmax of silybin by comparing with that of silybin given alone."( Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies.
Feng, SL; Li, YZ; Liu, CX; Liu, L; Liu, ZQ; Xie, Y; Yuan, ZW; Zhou, H, 2018
)
0.48
" Our method for SBN was applied to a comparative pharmacokinetic study on four different commercial silymarin products."( A Simple HPLC Method for the Quantitative Determination of Silybin in Rat Plasma: Application to a Comparative Pharmacokinetic Study on Commercial Silymarin Products.
Ha, ES; Han, DG; Kim, JM; Kim, MS; Lee, SK; Seo, SW; Sim, WY; Yoon, IS, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"Botanical medicines are frequently used in combination with therapeutic drugs, imposing a risk for harmful botanical-drug interactions (BDIs)."( An ex vivo approach to botanical-drug interactions: a proof of concept study.
Gurley, BJ; Markowitz, JS; Munoz, J; Wang, X; Zhu, HJ, 2015
)
0.42
"In the present study we have evaluated the synergistic effect of silibinin, a nontoxic phytotherapeutic agent in combination with doxorubicin, in advanced HCC using HEPG2 cells and an orthotopic rat model of HCC."( Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study.
Li, WG; Wang, HQ,
)
0.13
" This study investigates the synergistic effect of Silibinin combined with Pu-erh tea extract (PTE) against NAFLD and explores the suggested mechanism of action."( Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice.
Hu, WY; Li, XX; Ma, XH; Sun, H; Sun, TT; Zhou, WY, 2017
)
0.46
" This study is designed to evaluate the cytogenetic effects of flavonolignan silibinin in mouse bone marrow cells alone and in combination with methotrexate."( The cytogenetic effects of silibinin alone and in combination with methotrexate in mouse bone marrow.
Oufi, HG, 2018
)
0.48
" The purpose of this study was to investigate (1) the prevalence of hepatic steatosis in the general population and patients with chronic hepatitis B (CHB) and (2) to evaluate the effect of SC combined with therapeutic lifestyle changes (TLC) compared with TLC alone on hepatic steatosis in patients with CHB."( Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B.
Chen, EQ; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YJ; Zhang, DM, 2021
)
0.62
" Microbubbles in combination with ultrasound are promising vehicles for local drug delivery."( Evaluation of Silibinin-Loaded Microbubbles Combined with Ultrasound in Ovarian Cancer Cells: Cytotoxicity and Mechanisms.
Chen, B; Liu, J; Meng, W; Zhang, H; Zhou, L, 2022
)
0.72
"The present study determined the antitumour effects and molecular mechanism of silibinin-loaded microbubbles (SBMBs) in combination with ultrasound on ovarian cancer in vitro."( Evaluation of Silibinin-Loaded Microbubbles Combined with Ultrasound in Ovarian Cancer Cells: Cytotoxicity and Mechanisms.
Chen, B; Liu, J; Meng, W; Zhang, H; Zhou, L, 2022
)
0.72
" SBMBs in combination with ultrasound decreased A2780 cell viability in a dose- and time-dependent manner."( Evaluation of Silibinin-Loaded Microbubbles Combined with Ultrasound in Ovarian Cancer Cells: Cytotoxicity and Mechanisms.
Chen, B; Liu, J; Meng, W; Zhang, H; Zhou, L, 2022
)
0.72
"SBMBs in combination with ultrasound may enhance the cytotoxicity efficiency of SB via the promotion of apoptosis and cell cycle arrest in ovarian cancer cells and the inactivation of the STAT3, AKT and Erk signalling pathways."( Evaluation of Silibinin-Loaded Microbubbles Combined with Ultrasound in Ovarian Cancer Cells: Cytotoxicity and Mechanisms.
Chen, B; Liu, J; Meng, W; Zhang, H; Zhou, L, 2022
)
0.72

Bioavailability

Silybin-phosphatidylcholine is an orally bioavailable complex of silybin, a polyphenolic flavonolignan derived from milk thistle. Silybin has potential anticancer activity in preclinical models.

ExcerptReferenceRelevance
" Our results suggest that polyphenolic compounds might be potential structural bases and source to find and project nature-based, safe, orally bioavailable direct thrombin inhibitors."( Thrombin inhibitory activity of some polyphenolic compounds.
Bijak, M; Krotkiewski, H; Nowak, P; Pawlaczyk, I; Ponczek, M; Saluk, J; Wachowicz, B; Ziewiecki, R, 2014
)
0.4
" The findings in this study suggest that antiproliferative potency of silibinin and 2,3-dehydrosilibinin can be appreciably enhanced through suitable chemical modifications on the phenolic hydroxyl group at C-7 and that introduction of a chemical moiety with the potential to improve bioavailability through a linker to 7-OH in silibinin and 2,3-dehydrosilibinin would be a feasible strategy for the development of silibinin derivatives as anti-prostate cancer agents."( Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
Chen, QH; Parisis, K; Vue, B; Wang, G; Zhang, Q; Zhang, S; Zhang, X; Zheng, S, 2016
)
0.43
" However, silibinin has poor absorbance and bioavailability due to low water solubility, thereby limiting its clinical applications and therapeutic efficiency."( Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
Bai, G; Chu, Y; Gu, N; Li, S; Li, T; Li, W; Liu, C; Polachi, N; Sun, H; Wang, X; Wu, J; Zhang, Y; Zhou, S, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"To study a comparative bioavailability of Liverman capsule to Legaion capsule and Silymarin tablet (which contain silibinin) in 24 healthy volunteers."( Comparative bioavailability of silibinin in healthy male volunteers.
Jang, SW; Kim, EJ; Kim, JH; Kim, WB; Kim, YC; Kim, YG; Kwon, JW; Lee, ED; Lee, MG, 2003
)
0.32
"These results indicate that the absorption and the extent of relative oral bioavailability of silibinin after Liverman capsule were significantly faster and greater, respectively, than those after Legalon capsule and Silymarin tablet."( Comparative bioavailability of silibinin in healthy male volunteers.
Jang, SW; Kim, EJ; Kim, JH; Kim, WB; Kim, YC; Kim, YG; Kwon, JW; Lee, ED; Lee, MG, 2003
)
0.32
" silybin beta-galactoside, silybin beta-glucoside, silybin beta-maltoside, silybin beta-lactoside were synthesized in order to improve silybin water solubility and bioavailability (Kren et al."( Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes.
Dvorák, Z; Kosina, P; Maurel, P; Ulrichová, J, 2005
)
0.33
" Silybin-phosphatidylcholine complexed as a phytosome provides significant liver protection and enhanced bioavailability over conventional silymarin."( A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
Head, K; Kidd, P, 2005
)
0.33
" To compare the pharmacokinetic characteristics and bioavailability after oral administration of silybinphospholipid complex and silybin material in rats."( [Preparation of silybin-phospholipid complex and its bioavailability in rats].
Chen, ZP; Ping, QN; Song, YM; Xiao, YY, 2005
)
0.33
"It was concluded that after oral administration of silybin-phospholipid complex in rats the bioavailability of silybin increased greatly."( [Preparation of silybin-phospholipid complex and its bioavailability in rats].
Chen, ZP; Ping, QN; Song, YM; Xiao, YY, 2005
)
0.33
"The aim of the present study was to find a way of prepare silybin-phospholipid complex to make oral bioavailability of silybin increase and to study its physicochemical properties and to compare the pharmacokinetic characteristics and bioavailability after oral administration of silybin-phospholipid complex and silybin-N-methylglucamine in rats."( The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
Qineng, P; Yanyu, X; Yunmei, S; Zhipeng, C, 2006
)
0.33
"The absorption rate constant (k(a)) and the effective permeability (P(eff)) of SLB at 190 microg x mL(-1) were determined for each segment."( [The absorption characteristics of silybin in small intestine of rat].
Luan, LB; Zhao, N, 2006
)
0.33
" However, it has a low bioavailability after being administered orally on account of its low solubility in water."( Formulation and biopharmaceutical evaluation of silymarin using SMEDDS.
Chi, SC; Kim, TS; Park, JH; Woo, JS, 2007
)
0.34
" The potential for enhanced bioavailability of a phytosome complex containing phosphatidylcholine and silybin, the primary active flavonolignan in silymarin extract, was tested in dogs."( Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn, CR; Griffin, DW; Kettenacker, R, 2007
)
0.34
" The relative bioavailability of solid dispersion pellets in dogs based on quantification of silibinin was about five-fold that of the SME suspension confirming enhanced oral bioavailability."( In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating.
Lu, Y; Sun, N; Wu, W; Zhang, X, 2008
)
0.35
" Aiming at improving its poor bioavailability of oral products, galactosylated liposomes were introduced in this work for silibinin delivery and targeting to the lectin receptors present on the hepatocytes."( Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin.
Dube, D; Goyal, AK; Khatri, K; Mishra, N; Vyas, SP, 2010
)
0.36
" This protection of nano-silibinin might relate to its improved bioavailability compared to normal insoluble silibinin and could act as an anti-oxidative and anti-steatosis agent against ethanol-induced hepatotoxicity."( Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.
Meng, Q; Ruan, X; Shen, C, 2010
)
0.36
" Consequently, the absolute bioavailability (AB) of tamoxifen in the presence of silybinin (2."( Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Choi, JS; Choi, SJ; Kim, CS; Li, C; Park, CY, 2010
)
0.36
" A pharmacokinetics study in beagle dogs further confirmed the in vitro results and demonstrated that oral administration of silybin nanosuspensions significantly increase its bioavailability compared to the coarse powder."( In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery.
Duan, C; Feng, F; Jia, L; Liu, G; Liu, Z; Shi, Y; Wang, Y; Zhang, D; Zhang, Q; Zhang, X, 2010
)
0.36
" The purpose of this study was to investigate the effect of oral silibinin on the bioavailability and pharmacokinetics of orally and intravenously administered paclitaxel in rats."( Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Choi, JS; Lee, CK, 2010
)
0.36
" The pharmacokinetic characteristics and bioavailability after oral administration of silybin-mixed micelles and silybin-N-methylglucamine were compared in dogs."( Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.
Cao, X; Peng, M; Qiu, H; Tong, SS; Wang, L; Xu, XM; Yu, JN; Zhu, Y, 2010
)
0.36
" After oral administration to dogs, the relative bioavailability of mixed micelles versus silybin-N-methylglucamine in dogs was 252."( Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.
Cao, X; Peng, M; Qiu, H; Tong, SS; Wang, L; Xu, XM; Yu, JN; Zhu, Y, 2010
)
0.36
"Sodium cholate/phospholipid-mixed micelles are promising carriers in orally delivery of silybin, considering their capability of enhancing bioavailability and large-scale production."( Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.
Cao, X; Peng, M; Qiu, H; Tong, SS; Wang, L; Xu, XM; Yu, JN; Zhu, Y, 2010
)
0.36
" Consequently, the absolute bioavailability of loratadine in the presence of silybinin (1."( Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
Choi, JS; Lee, MY; Li, C, 2010
)
0.36
" The relative oral bioavailability of silybin-dendrimer complex calculated on the basis of AUC(0-∞) was about 178% as compared with silybin."( Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin.
Chen, Q; Gao, W; Huang, X; Wu, Z; Yu, B, 2011
)
0.37
" Results indicate that the bioavailability of silybin phytosome is higher than that of silymarin and is less influenced by liver damage; silybin does not show significant interactions with other drugs and at doses < 10 g/d has no significant side effects."( Silybin and the liver: from basic research to clinical practice.
Festi, D; Loguercio, C, 2011
)
0.37
"The aim of the work was to produce a delivery system for Silybum Marianum dry extract with enhanced oral bioavailability by combining two technologies (mechanochemical activation and spray congealing)."( A new approach to enhance oral bioavailability of Silybum Marianum dry extract: association of mechanochemical activation and spray congealing.
Albertini, B; Franceschinis, E; Hasa, D; Lenaz, D; Locatelli, I; Passerini, N; Perissutti, B; Voinovich, D, 2012
)
0.38
"Mesoporous silica SBA-15 (SC) and template occluded SBA-15 (SP) were used to increase the bioavailability of silybin, an extremely poorly water soluble drug."( Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials.
Cai, X; Fu, T; Guo, L; Lu, J; Zhang, L; Zhu, H, 2012
)
0.38
" Science has contributed to improving the bioavailability of silibinin thus making it more effective."( [Silibinin and its hepatoprotective action from the perspective of a toxicologist].
Kostek, H; Lewandowska-Stanek, H; Majewska, M; Szponar, J; Tchórz, M, 2012
)
0.38
" Flavonoids such as silibinin, green tea polyphenols, genistein, curcumin have shown great promise, but avenues to improve their bioavailability are requisite."( Advances in prostate cancer chemoprevention: a translational perspective.
Nambiar, D; Singh, RP, 2013
)
0.39
" Studies of the metabolism, pharmacokinetics, potentional drug--drug interactions and increasing bioavailability of these flavonolignans play an important facet of possible therapeutical use of these compounds."( Biotransformation of silybin and its congeners.
Gabrielová, E; Křen, V; Marhol, P; Modrianský, M; Purchartová, K, 2013
)
0.39
" In conclusion, it is possible to increase the bioavailability of poorly soluble drugs by preparing its water-soluble derivative."( In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative.
Li, LC; Mao, S; Ni, R; Sun, W; Xu, D, 2015
)
0.42
" Consequently, the bioavailability and therapeutic effective of silybin is also limited."( Recent advances in the nanotechnology-based drug delivery of Silybin.
Wang, Q; Wang, Y; Zhang, D; Zhang, L, 2014
)
0.4
" However, its hydrophobic nature limits its bioavailability compromising in vivo biological activities."( Fabrication, characterization and bioevaluation of silibinin loaded chitosan nanoparticles.
Babu Bikkina, DJ; Chinde, S; Kulhari, H; Nikhila, N; Pooja, D; Raghavendra, YM; Sreedhar, B; Tiwari, AK, 2014
)
0.4
" Silibinin possesses a wide variety of biological applications including anticancer activities but poor aqueous solubility and poor bioavailability limit its potential and efficacy at the tumor sites."( Enhanced cytotoxicity and apoptosis-induced anticancer effect of silibinin-loaded nanoparticles in oral carcinoma (KB) cells.
Gohulkumar, M; Gurushankar, K; Krishnakumar, N; Rajendra Prasad, N, 2014
)
0.4
" The aim of the present study was to develop lecithin-based carrier system of silymarin by incorporating phytosomal-liposomal approach to increase its oral bioavailability and to make it target-specific to the liver for enhanced hepatoprotection."( Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
Deshpande, P; Jain, P; Kumar, N; Kutty, NG; Mathew, G; Rai, A; Raj, PV; Rao, CM; Reddy, ND; Udupa, N, 2014
)
0.4
" The liposomal formulation yielded a three and half fold higher bioavailability of silymarin as compared with silymarin suspension."( Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
Deshpande, P; Jain, P; Kumar, N; Kutty, NG; Mathew, G; Rai, A; Raj, PV; Rao, CM; Reddy, ND; Udupa, N, 2014
)
0.4
"Incorporating the phytosomal form of silymarin in liposomal carrier system increased the oral bioavailability and showed better hepatoprotection and better anti-inflammatory effects compared with silymarin suspension."( Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
Deshpande, P; Jain, P; Kumar, N; Kutty, NG; Mathew, G; Rai, A; Raj, PV; Rao, CM; Reddy, ND; Udupa, N, 2014
)
0.4
"Cyclodextrins (CDs) are a well-known class of supermolecules that have been widely used to protect drugs against conjugation and metabolic inactivation as well as to enhance the aqueous solubility and hence to ameliorate the oral bioavailability of sparingly soluble drug molecules."( Investigation of the interactions of silibinin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods.
Archontaki, H; Becker-Baldus, J; Chatziathanasiadou, M; Chatzigeorgiou, P; Chatzikonstantinou, AV; Glaubitz, C; Kefala, E; Kellici, TF; Leonis, G; Mavromoustakos, T; Ntountaniotis, D; Papadopoulos, MG; Tzakos, AG; Tzimas, S; Valsami, G; Viras, K, 2015
)
0.42
" Silymarin-loaded SNEDDS were successfully developed to improve the dissolution, permeability, and oral bioavailability of silymarin."( Self-nanoemulsifying drug delivery systems ameliorate the oral delivery of silymarin in rats with Roux-en-Y gastric bypass surgery.
Aljuffali, IA; Chang, CC; Chen, CH; Fang, JY; Shih, TH; Yeh, TS, 2015
)
0.42
" Hence, emulsomes might represent a promising system for improving the bioavailability of lipophilic drugs."( Preparation and performance evaluation of emulsomes as a drug delivery system for silybin.
Chen, Z; Zhou, X, 2015
)
0.42
"Silibinin, the main active component of Silybum marianum is a hepatoprotective and antioxidant agent with antitumor effect, exhibiting very low aqueous solubility and oral bioavailability limiting its use in therapeutics."( Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product.
Archontaki, H; Balafas, E; Christodoulou, E; Dokoumetzidis, A; Kechagia, IA; Kostomitsopoulos, N; Tzimas, S; Valsami, G, 2015
)
0.42
"Silybin-phosphatidylcholine is an orally bioavailable complex of silybin, a polyphenolic flavonolignan derived from milk thistle, endowed with potential anticancer activity in preclinical models."( A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.
Aristarco, V; Bonanni, B; Caldarella, P; Cazzaniga, M; DeCensi, A; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Mora, S; Morazzoni, P; Pagani, G; Petrangolini, G; Pruneri, G; Puccio, A; Riva, A; Serrano, D, 2016
)
0.43
"In order to enhance oral bioavailability and liver targeting delivery of silybin, two amphiphilic hyaluronic acid derivatives, hyaluronic acid-deoxycholic acid (HA-adh-DOCA) and hyaluronic acid-glycyrrhetinic acid (HA-adh-GA) conjugates, were designed and synthesized."( Liver-targeting self-assembled hyaluronic acid-glycyrrhetinic acid micelles enhance hepato-protective effect of silybin after oral administration.
Gong, M; Guan, H; Han, X; He, R; Li, J; Wang, M; Wang, Z; Xu, Y; Yue, Z, 2016
)
0.43
" In conclusion, this povidone-mixed micelle-based microparticle was successfully prepared to enhance the oral bioavailability of silybin."( In Vitro Release and Bioavailability of Silybin from Micelle-Templated Porous Calcium Phosphate Microparticles.
Omari-Siaw, E; Wang, M; Xu, X; Yu, J; Zeng, J; Zhang, Y; Zhu, Y, 2016
)
0.43
" Advanced drug forms may improve the bioavailability of these compounds."( Positive effects of different drug forms of silybin in the treatment of metabolic syndrome.
Kazdová, L; Malínská, H; Matušková, Z; Oliyarnyk, O; Poruba, M; Tozzi di Angelo, I; Večeřa, R, 2015
)
0.42
" The findings in this study suggest that antiproliferative potency of silibinin and 2,3-dehydrosilibinin can be appreciably enhanced through suitable chemical modifications on the phenolic hydroxyl group at C-7 and that introduction of a chemical moiety with the potential to improve bioavailability through a linker to 7-OH in silibinin and 2,3-dehydrosilibinin would be a feasible strategy for the development of silibinin derivatives as anti-prostate cancer agents."( Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
Chen, QH; Parisis, K; Vue, B; Wang, G; Zhang, Q; Zhang, S; Zhang, X; Zheng, S, 2016
)
0.43
"The therapeutic potentials of silibinin - a phytochemical isolated from milk thistle plants - have not been fully realized due to its poor oral bioavailability caused by the low aqueous solubility."( A supersaturating delivery system of silibinin exhibiting high payload achieved by amorphous nano-complexation with chitosan.
Dong, B; Hadinoto, K; Nguyen, MH; Yu, H, 2016
)
0.43
" To overcome this limitation, we developed highly bioavailable silibinin nanoparticles (SB-NPs) and evaluated their efficiency against HCV infection."( Highly bioavailable silibinin nanoparticles inhibit HCV infection.
Chang, SP; Chung, CY; Hsu, WC; Jassey, A; Lin, CC; Lin, LT; Liu, CH; Richardson, CD; Shields, J; Tai, CJ; Tyrrell, DLJ; Yen, MH, 2017
)
0.46
" The moderate hepatoprotective and oxidant potentials of SBN could be due to its low bioavailability and this deficiency could be prevented by supplementation of phosphatidylcholines and studies are warranted on these lines to improve the therapeutic efficiency of SBN."( Zidovudine and isoniazid induced liver toxicity and oxidative stress: Evaluation of mitigating properties of silibinin.
Karthikeyan, S; Raghu, R, 2016
)
0.43
" However, silibinin has poor absorbance and bioavailability due to low water solubility, thereby limiting its clinical applications and therapeutic efficiency."( Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
Bai, G; Chu, Y; Gu, N; Li, S; Li, T; Li, W; Liu, C; Polachi, N; Sun, H; Wang, X; Wu, J; Zhang, Y; Zhou, S, 2016
)
0.43
"A new silybin nanocrystal self-stabilized Pickering emulsion (SN-SSPE) has been developed using a high pressure homogenization method to improve the oral bioavailability of silybin."( A new drug nanocrystal self-stabilized Pickering emulsion for oral delivery of silybin.
Liu, C; Wang, F; Wang, J; Yi, T; Zhang, J, 2017
)
0.46
" It has demonstrated anti-tumoural activity against many types of malignancies; however, due to its hydrophobic structure, it has poor water solubility, bioavailability and permeability across intestinal epithelial cells."( Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line.
Hakamivala, A; Kashanian, S; Maharat, Z; Moghassemi, S; Omidfar, K; Yazdi Rouholamini, SE, 2018
)
0.48
" The prepared NPs were characterized using different analytical techniques such as scanning electron microscopy (SEM), fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray powder diffractometry (XRD) and were sifted for their bioavailability through in vitro dissolution and solubility studies."( Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability.
Amin, MU; Faidah, HS; Haseeb, A; Khan, S; Khurram, M; Sadiq, A; Sahibzada, MUK, 2017
)
0.46
" The oral bioavailability of SB is enhanced by 5-7-fold in comparison with a fast-release formulation."( In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability.
Chen, D; He, H; Li, Y; Lu, Y; Ma, Y; Qi, J; Wu, W; Xia, F; Zhang, W, 2017
)
0.46
" A group of protective compounds are the flavonoids but their intestinal absorbtion and bioavailability are low and impredictible."( Silybin Against Liver Ischemia-Reperfusion Injury: Something Old, Something New….
Oltean, M, 2018
)
0.48
" Results of pharmacokinetic studies on rats then confirmed a desirable enhancement in the oral bioavailability of SLB by OCC-SLB micelles compared with a stock SLB suspension solution."( The efficiency and mechanism of N-octyl-O, N-carboxymethyl chitosan-based micelles to enhance the oral absorption of silybin.
Chen, Q; Fu, Y; Huo, M; Liang, J; Liu, J; Liu, Y; Tang, X; Yin, T; Zhang, Y; Zhou, J, 2018
)
0.48
"The purpose of this study was to compare the bioavailability between 2 milk thistle-containing dietary supplements, Product B and IsaGenesis, in healthy volunteers."( Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.
Frye, RF; Gumpricht, E; Hogan, RM; Li, WY; Markowitz, JS; Mohandas, R; Yu, G, 2018
)
0.48
"The IsaGenesis soft gel formulation provided substantially greater absorption and bioavailability of silybin A and silybin B relative to the powdered Product B supplement."( Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.
Frye, RF; Gumpricht, E; Hogan, RM; Li, WY; Markowitz, JS; Mohandas, R; Yu, G, 2018
)
0.48
"A new silybin nanocrystallines self-stabilizing Pickering emulsion(SN-SSPE) was developed using the high pressure homogenization method to improve the oral bioavailability of silybin."( [Preparation and evaluation of silybin nanocrystallines self-stabilizing Pickering emulsion].
Liu, C; Yi, T; Zhang, J; Zhang, JF, 2016
)
0.43
" A quantitative structure-activity relationship (QSAR) model based on data from a parallel artificial membrane permeability assay (PAMPA) was used to estimate bioavailability after oral administration."( ADME/Tox Properties and Biochemical Interactions of Silybin Congeners: In silico Study.
Al Sharif, M; Alov, P; Diukendjieva, A; Pajeva, I; Pencheva, T; Tsakovska, I, 2017
)
0.46
"This study explored the feasibility of using smart nanocaged carrier technology for the delivering of multifunctional mPEG-chitosan stabilized silybin nanocrystals and to enhancing the long-term stability, dissolution velocity and bioavailability of the water insoluble drugs."( Design, optimization and in vitro-in vivo evaluation of smart nanocaged carrier delivery of multifunctional PEG-chitosan stabilized silybin nanocrystals.
Liu, Y; Wang, Y; Zhao, J, 2019
)
0.51
" Therefore, we sought to assess and compare the pharmacokinetic properties and bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules and conventional silymarin tablets in healthy Mexican volunteers."( Superior silybin bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers.
Dibildox-Martinez, M; Flores-Murrieta, FJ; Méndez-Sánchez, N; Sánchez-Medal, R; Sosa-Noguera, J, 2019
)
0.51
" Fasting participants received either 45 mg silybin-phosphatidylcholine complex or 70 mg silymarin to assess which formulation provided better bioavailability of silybin."( Superior silybin bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers.
Dibildox-Martinez, M; Flores-Murrieta, FJ; Méndez-Sánchez, N; Sánchez-Medal, R; Sosa-Noguera, J, 2019
)
0.51
"Although silybin serves as a well-known hepatoprotective agent with prominent anti-inflammatory, anti-oxidant and anti-fibrotic activities, its low bioavailability limits its application in the treatment of chronic liver diseases."( Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2.
Bi, X; Liu, Z; Qu, B; Xie, Y; Yuan, Z; Zhou, H, 2019
)
0.51
"We hypothesized that inhibiting efflux transporter(s) and/or glucuronidation by piperine might enhance the bioavailability and efficacy of silybin."( Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2.
Bi, X; Liu, Z; Qu, B; Xie, Y; Yuan, Z; Zhou, H, 2019
)
0.51
" This in vivo rat study demonstrated that product #4 significantly enhanced the relative oral bioavailability of SBN, as compared to product #1-3."( A Simple HPLC Method for the Quantitative Determination of Silybin in Rat Plasma: Application to a Comparative Pharmacokinetic Study on Commercial Silymarin Products.
Ha, ES; Han, DG; Kim, JM; Kim, MS; Lee, SK; Seo, SW; Sim, WY; Yoon, IS, 2019
)
0.51
"Most of the herbal origin drugs possess water insoluble active constituents which lower the bioavailability and increase systemic clearance after administration of repeated or higher dose of drug."( Nanotherapeutic silibinin: An insight of phytomedicine in healthcare reformation.
Shende, P; Takke, A, 2019
)
0.51
" However, inconsistent results are noted in the different clinical studies due to the low bioavailability of silymarin."( Metabolism, Transport and Drug-Drug Interactions of Silymarin.
Xie, Y; Yuan, J; Zhang, D; Zhang, J, 2019
)
0.51
" However, low bioavailability seriously limits wide-application of SB in biomedical niche."( Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism.
Chen, SY; Pang, XC; Suguro, R; Xie, Y; Yuan, ZW; Zhu, YZ, 2020
)
0.56
" However, it seems that silibinin has a variety of limitations and poor bioavailability is the most important factor restricting its wide application."( Nano-soldiers Ameliorate Silibinin Delivery: A Review Study.
Ahmadi, Z; Ashrafizadeh, M; Farkhondeh, T; Mohammadinejad, R; Samarghandian, S, 2020
)
0.56
" In order to improve the low bioavailability of silybin, a novel formulation of phytosome-nanosuspensions for silybin shielding termed as SPCs-NPs, has been developed herein for hepatoprotection efficacy."( Phytosome-nanosuspensions for silybin-phospholipid complex with increased bioavailability and hepatoprotection efficacy.
Chi, C; Ding, Y; Liu, Y; Nie, H; Zhang, C; Zhou, J, 2020
)
0.56
"To investigate comparative in vitro and in vivo performance of lipid vesicular and particulate systems in escalating oral bioavailability for superior hepatoprotection."( Lipid nanoconstructs for superior hepatoprotection: In vitro assessments as predictive tool for in vivo translation.
Dhawan, V; Fahr, A; Lokras, A; Nagarsenker, M; Saraf, M; Sutariya, B; Thamm, J; Warawdekar, U, 2020
)
0.56
"5 fold increase in bioavailability was evident in vivo."( Lipid nanoconstructs for superior hepatoprotection: In vitro assessments as predictive tool for in vivo translation.
Dhawan, V; Fahr, A; Lokras, A; Nagarsenker, M; Saraf, M; Sutariya, B; Thamm, J; Warawdekar, U, 2020
)
0.56
" In addition, we studied the bioavailability potential of mycotoxins and silibinin utilizing an in vitro transwell system with differentiated human colon adenocarcinoma cells (Caco-2) simulating mycotoxin transfer through the intestinal epithelial barrier."( In Silico and In Vitro Studies of Mycotoxins and Their Cocktails; Their Toxicity and Its Mitigation by Silibinin Pre-Treatment.
Augustynkova, K; Dobiasova, S; Fenclova, M; Hajslova, J; Jelenova, N; Rehorova, K; Ruml, T; Stranska-Zachariasova, M; Tran, VN; Viktorova, J; Vitek, L, 2020
)
0.56
"The objective of this work was to investigate the capacity of mogroside V (MOG-V), a food additive, as a novel carrier to improve the bioavailability and liver distribution of silybin (SLY)."( Evaluation of Mogroside V as a Promising Carrier in Drug Delivery: Improving the Bioavailability and Liver Distribution of Silybin.
Chen, Y; Gong, C; Luo, Y; Mo, L; Song, T; Wei, M; Wu, C; Zhang, J, 2020
)
0.56
"Silibinin- and cryptotanshinone-co-loaded pW-LPNs efficiently penetrate intestinal barriers, thereby enhancing the oral bioavailability of the drug loads."( Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.
Chen, H; Feng, N; He, Y; Hou, X; Liu, Y; Shen, J; Shi, J; Wang, Z; Xie, X, 2020
)
0.56
"Nanocrystals, due to high drug loading efficiency, have drawn large attention as nanotechnology to enhance solubility and bioavailability of poorly soluble drugs."( Mucoadhesive nanocrystal-in-microspheres with high drug loading capacity for bioavailability enhancement of silybin.
Fu, T; Han, J; Li, H; Li, J; Qiao, H; Wang, L; Wang, Y; Wang, Z; Yang, Y, 2021
)
0.62
"69 times respectively of that in SLB suspension group, with a relative bioavailability of 578."( [Effects of HPMCAS MF on absorption of silybin from supersaturable self-nanoemulsifying drug delivery system].
Ding, HB; Jiang, QY; Lai, ZT; Liao, ZG; Yuan, QL, 2021
)
0.62
" However, its low solubility and poor bioavailability limit its clinical potential in biomedical applications."( Evaluation of Silibinin-Loaded Microbubbles Combined with Ultrasound in Ovarian Cancer Cells: Cytotoxicity and Mechanisms.
Chen, B; Liu, J; Meng, W; Zhang, H; Zhou, L, 2022
)
0.72
" However, the complex hydrophobic nature and inadequate bioavailability of SIL hinder its efficiency at tumor sites."( Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets.
Dadashpour, M; Firouzi Amandi, A; Mousapour, A; Pourgholi, A; Zarghami, N, 2021
)
0.62
" However, the poor brain targeting ability and low bioavailability limit its wide application."( Biomimetic silibinin-loaded macrophage-derived exosomes induce dual inhibition of Aβ aggregation and astrocyte activation to alleviate cognitive impairment in a model of Alzheimer's disease.
Huang, L; Huo, Q; Qi, Y; Shi, Y; Sui, H; Zhao, L, 2021
)
0.62
" However, its oral bioavailability is low due to poor water solubility."( Synthesis of Pore-Size-Tunable Mesoporous Silica Nanoparticles by Simultaneous Sol-Gel and Radical Polymerization to Enhance Silibinin Dissolution.
Abedanzadeh, M; Abedi, M; Abolmaali, S; Shafiee, M; Tamaddon, A, 2021
)
0.62
" High-performance liquid chromatography was used to carry out bioavailability studies of SIBP."( Silybin phytosome attenuates cerebral ischemia-reperfusion injury in rats by suppressing oxidative stress and reducing inflammatory response: In vivo and in silico approaches.
Pasala, PK; Rudrapal, M; Umar, AK; Uppara, RK; Zothantluanga, JH, 2022
)
0.72
" In addition, SLB-HSA NCs significantly improved the bioavailability compared with free SLB in pharmacokinetic study."( Albumin-Based Silibinin Nanocrystals Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy.
Fang, C; Gong, T; Li, Y; Luo, S; Yang, Y; Zhang, R; Zhang, Z; Zhao, T, 2023
)
0.91
" However, its rapid metabolism and low bioavailability limit its therapeutic effects."( Increased therapeutic effect of nanotized silibinin against glycation and diabetes: An in vitro and in silico-based approach.
Khalid, A; Naseem, I, 2023
)
0.91
" Silymarin extract and its major compound silibinin (SLB) possess robust antioxidant properties by inducing ROS elimination; however, low bioavailability and rapid metabolism limit their applications."( Alleviation of acetaminophen-induced liver failure using silibinin nanoliposomes: An in vivo study.
Alavizadeh, SH; Doagooyan, M; Gheybi, F; Hoseinian, A; Houshangi, K; Jaafari, MR; Khoddamipour, Z; Khooei, A; Papi, A; Sahebkar, A, 2023
)
0.91
"Silybin (SLB) as an effective hepatoprotective phytomedicine has been limited by its hydrophobicity, poor bioavailability and accumulation at lesion sites."( Combined Amphiphilic Silybin Meglumine Nanosuspension Effective Against Hepatic Fibrosis in Mice Model.
Chen, D; Feng, J; Gong, T; Guo, C; He, Q; Li, J; Song, X; Tan, T; Tan, Y; Yang, Q, 2023
)
0.91
" In addition, dissolution, trans-epithelial permeability, and bioavailability experiments were conducted to evaluate the absorption and distribution of drugs."( Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.
Cui, J; Jiang, J; Li, R; Ma, X; Ren, L; Wang, L; Yu, H; Yu, X; Zhang, W, 2024
)
1.44
" Furthermore, BSS significantly increased the bioavailability of SIY in both plasma and the liver (2."( Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.
Cui, J; Jiang, J; Li, R; Ma, X; Ren, L; Wang, L; Yu, H; Yu, X; Zhang, W, 2024
)
1.44

Dosage Studied

Fifty C57BL/6J mice were divided into five groups: control, model, low dosage esculin (oral, 20 mg/kg), high dosage Esculin and silybin. 38 cases in control group, only Silybin Meglumine Tablets was used. If these results are confirmed in clinical trials, the tamoxifen dosage should be adjusted.

ExcerptRelevanceReference
"Acetaminophen, a safe analgesic when dosed properly but hepatotoxic at overdoses, has been reported to induce DNA strand breaks but it is unclear whether this event preceeds hepatocyte toxicity or is only obvious in case of overt cytotoxicity."( Antioxidants protect primary rat hepatocyte cultures against acetaminophen-induced DNA strand breaks but not against acetaminophen-induced cytotoxicity.
El-Bahay, C; Hanelt, S; Kahl, R; Lewerenz, V; Nastevska, C; Röhrdanz, E, 2003
)
0.32
" At the same time, silibinin is also physiologically available in different organs of the body including plasma and prostate, which is generally required for the pharmacological dosing and translational mechanistic studies of the compound."( A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
Agarwal, R; Singh, RP, 2004
)
0.32
" A major problem in the development of an oral solid dosage form of this drug is the extremely poor aqueous solubility."( Solubility of silybin in aqueous poly(ethylene glycol) solution.
Bai, TC; Hu, J; Huang, CG; Yan, GB; Zhang, HL, 2006
)
0.33
" A group of eight beagles (four males, four females) were dosed orally with a silybin-phosphatidylcholine complex (SPC) and a commercially available standardized silymarin extract containing equivalent levels of silybin."( Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn, CR; Griffin, DW; Kettenacker, R, 2007
)
0.34
" Repeated dosing was administered intraperitoneally every 4 to 6 hours for 48 hours."( Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model.
Betten, DP; Clark, RF; Favata, M; Hernandez, M; Richardson, WH; Riffenburgh, RH; Tanen, DA; Tong, TC, 2007
)
0.34
" It was found to be linear, accurate, precise, specific, robust and stability-indicating and can be applied for quality control and standardization of several multi-component hepatoprotective formulations as well as for stability testing of different dosage forms."( Stability-indicating HPTLC method for quantitative estimation of silybin in bulk drug and pharmaceutical dosage form.
Ahmad, S; Ali, J; Alka, A; Baboota, S; Parveen, R, 2010
)
0.36
" 38 cases in control group, only Silybin Meglumine Tablets was used, method and dosage were the same as treatment group."( [Influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B].
Ding, H; Gu, XB; Wang, D; Wu, HY; Xu, YQ; Yang, XJ; Zhang, B; Zhu, YF, 2009
)
0.35
" If these results are confirmed in clinical trials, the tamoxifen dosage should be adjusted when tamoxifen is administered with silybinin or silybinin-containing dietary supplements."( Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Choi, JS; Choi, SJ; Kim, CS; Li, C; Park, CY, 2010
)
0.36
"89 in the 10 or 15 and 20mg/kg/day dosing groups, respectively (p=0."( Understanding silibinin's modes of action against HCV using viral kinetic modeling.
Dahari, H; Ferenci, P; Guedj, J; Perelson, AS; Pohl, RT, 2012
)
0.38
" Collectively, oral dosage of MTE containing silibinin in the preclinical setting is effective in preventing estrogen deficiency-induced bone loss."( Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis.
Gong, JH; Han, SJ; Kang, MK; Kang, YH; Kim, JL; Kim, YH, 2013
)
0.39
" Also, because of the potential interactions of SB and co-administered medicines, it might be necessary to adjust the dosage in the clinical medication of liver disease."( Reversing effects of silybin on TAA-induced hepatic CYP3A dysfunction through PXR regulation.
Hao, HP; Wang, GJ; Wang, H; Wang, ZX; Xie, Y, 2013
)
0.39
" Neither changes in immunosuppressant through levels nor dosage adjustments were necessary."( Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
Brambilla, N; Bringiotti, RS; Castellaneta, A; Castellaneta, NM; D'Amato, M; Di Leo, A; Giacovelli, G; Rendina, M; Rizzi, SF; Rovati, L; Zappimbulso, M, 2014
)
0.4
" However, the current dosage form of the drug does not target the liver and inflammatory cells selectively."( Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
Deshpande, P; Jain, P; Kumar, N; Kutty, NG; Mathew, G; Rai, A; Raj, PV; Rao, CM; Reddy, ND; Udupa, N, 2014
)
0.4
" This work aimed to develop appropriate drug ratios and dosing for each FDC."( Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S, 2015
)
0.42
" Monte-Carlo simulations of WHO and FDA dosing recommendations were performed to assess their ability to provide optimal exposure in children weighing 4 to 25 kg based on consensus plasma targets."( Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S, 2015
)
0.42
" Given the recommended drug ratios, the dosage for the 4-5."( Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S, 2015
)
0.42
" Dosage adjustment may be necessary for subjects of different genotypes to ensure comparative exposures."( The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin.
Chen, Y; Huang, WH; Liu, J; Tan, ZR; Wang, LS; Wang, YC; Zhou, YX, 2015
)
0.42
" SIL effectiveness in blocking viral production was similar among dosing groups (median ε = 77%)."( Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
Akamatsu, S; Canini, L; Chayama, K; Dahari, H; DebRoy, S; Hayes, CN; Hiraga, N; Imamura, M; Perelson, AS; Persiani, S; Pohl, RT; Tateno, C; Uprichard, SL, 2016
)
0.43
"5 mg/kg per week of Peg-IFN plus RBV and placebo, while Group B received the same dosage of Peg-IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months."( Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.
Bertino, G; Caraci, F; Chisari, G; Drago, F; Greco, C; Malaguarnera, G; Malaguarnera, M; Motta, M; Nunnari, G; Vacante, M; Vecchio, M, 2016
)
0.43
" Moreover, the co-loaded nanoparticles efficiently discharged the two drugs at the prospective dosage ratio specifically in acid endo/lysosome mimic environments."( Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation.
Cai, H; Huo, M; Li, L; Wang, H; Yin, T; Zhang, P; Zhang, Y; Zhou, J, 2020
)
0.56
" The problem of low energy emulsification methods is the high dosage of surfactant and co-surfactant which has potential biosecurity issues."( Engineering of Long-Term Stable Transparent Nanoemulsion Using High-Gravity Rotating Packed Bed for Oral Drug Delivery.
Chen, JF; Le, Y; Wang, CQ; Wang, JX; Wu, HR, 2020
)
0.56
"Fifty C57BL/6J mice were divided into five groups: control, model, low dosage esculin (oral, 20 mg/kg), high dosage esculin (oral, 40 mg/kg), and silybin (oral, 105 mg/kg)."( Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1/NF-
Chen, J; Chen, Z; Yang, XD; Yang, YY; Ye, L, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
flavonolignanAny lignan condensed with a 2-aryl-1-benzopyran skeleton and its substituted derivatives.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
benzodioxineAny organic heterobicyclic compound containing ortho-fused benzene and dioxine rings.
secondary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing one hydrogen and one organyl group. Secondary alpha-hydroxy ketones are also known as acyloins, and are formally derived from reductive coupling of two carboxylic acid groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Drug induction of bile acid pathway025

Protein Targets (91)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.25890.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.99530.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency35.79120.002541.796015,848.9004AID1347395; AID1347398
15-lipoxygenase, partialHomo sapiens (human)Potency25.11890.012610.691788.5700AID887
pregnane X receptorRattus norvegicus (Norway rat)Potency70.79460.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency43.32200.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency32.40800.173734.304761.8120AID1346859; AID1346924
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency32.40800.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency26.46000.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency26.92960.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency14.20700.000221.22318,912.5098AID588515; AID743035; AID743036; AID743053; AID743063
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency14.12540.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency14.12540.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency23.65590.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.67230.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency43.90400.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency9.77170.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency29.75830.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.20580.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.09230.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency54.94500.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency39.81070.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency60.94410.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.76410.000229.305416,493.5996AID1259248; AID588514; AID743069; AID743075; AID743078; AID743079
GVesicular stomatitis virusPotency8.70900.01238.964839.8107AID1645842
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.49130.001024.504861.6448AID588534; AID588535; AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency27.62160.001019.414170.9645AID588537; AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.20980.023723.228263.5986AID743222; AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency48.62310.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.60320.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency121.60000.001628.015177.1139AID1259385
Histone H2A.xCricetulus griseus (Chinese hamster)Potency112.72900.039147.5451146.8240AID1224845
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency125.89200.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.13170.000323.4451159.6830AID743065
heat shock protein beta-1Homo sapiens (human)Potency33.48890.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency49.62010.000627.21521,122.0200AID651741; AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency15.84890.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.20600.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency20.31480.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.01780.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency8.70900.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency8.70900.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency18.83360.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency35.48131.995325.532750.1187AID624288
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency8.70900.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency8.70900.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)6.90000.03403.987110.0000AID1603425; AID1603430
Polyphenol oxidase 2Agaricus bisporusKi4.57500.00063.28838.8900AID1603426; AID1603428; AID1603431; AID1603433
ProthrombinHomo sapiens (human)IC50 (µMol)22.95000.00000.710710.0000AID768890; AID768929
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)21.00000.03703.385910.0000AID768888
Trypsin-1Homo sapiens (human)IC50 (µMol)3.70000.00351.532110.0000AID768889
Trypsin-2Homo sapiens (human)IC50 (µMol)3.70000.00351.58464.4000AID768889
Cytochrome P450 3A4Homo sapiens (human)Ki98.66670.00011.41629.9000AID589119; AID589150
Cytochrome P450 2C9 Homo sapiens (human)Ki5.00000.00031.684210.0000AID589083
Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase Rattus norvegicus (Norway rat)IC50 (µMol)80.30000.00402.25236.0000AID449301
Trypsin-3Homo sapiens (human)IC50 (µMol)3.70000.00351.58464.4000AID768889
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)4.26580.10472.71957.0795AID977603
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki3.27000.08002.46889.8000AID977604
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)6.16590.05002.37979.7000AID977600
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki3.37000.04401.36305.0000AID977601
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)IC50 (µMol)4.50000.55003.70836.1000AID1214763
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)2.70000.10472.71957.0795AID1214762
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)9.70000.05002.37979.7000AID1214761
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)Kd18.60000.00000.01010.0387AID768894
ATP-dependent translocase ABCB1Mus musculus (house mouse)Kd6.80002.20005.18336.8000AID150738
Heat shock protein HSP 90-alphaHomo sapiens (human)Kd500.00000.00030.94889.8000AID1726505
Heat shock protein HSP 90-betaHomo sapiens (human)Kd500.00000.00031.33309.8000AID1726505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusKis15.65002.90005.33008.8500AID1603429; AID1603434
Xanthine dehydrogenase/oxidaseBos taurus (cattle)Km55.45001.80002.78003.7000AID424718; AID424719; AID424720; AID424721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (203)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseBos taurus (cattle)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
telomere maintenance via telomeraseHeat shock protein HSP 90-alphaHomo sapiens (human)
neuron migrationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein phosphorylationHeat shock protein HSP 90-alphaHomo sapiens (human)
activation of innate immune responseHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of defense response to virus by hostHeat shock protein HSP 90-alphaHomo sapiens (human)
skeletal muscle contractionHeat shock protein HSP 90-alphaHomo sapiens (human)
mitochondrial transportHeat shock protein HSP 90-alphaHomo sapiens (human)
response to unfolded proteinHeat shock protein HSP 90-alphaHomo sapiens (human)
response to heatHeat shock protein HSP 90-alphaHomo sapiens (human)
response to coldHeat shock protein HSP 90-alphaHomo sapiens (human)
response to xenobiotic stimulusHeat shock protein HSP 90-alphaHomo sapiens (human)
response to salt stressHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of lamellipodium assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
cardiac muscle cell apoptotic processHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein ubiquitinationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein polymerizationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of interferon-beta productionHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein localizationHeat shock protein HSP 90-alphaHomo sapiens (human)
protein refoldingHeat shock protein HSP 90-alphaHomo sapiens (human)
response to cocaineHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein import into nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of apoptotic processHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein-containing complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
protein unfoldingHeat shock protein HSP 90-alphaHomo sapiens (human)
response to estrogenHeat shock protein HSP 90-alphaHomo sapiens (human)
protein insertion into mitochondrial outer membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein catabolic processHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of cell sizeHeat shock protein HSP 90-alphaHomo sapiens (human)
response to antibioticHeat shock protein HSP 90-alphaHomo sapiens (human)
protein stabilizationHeat shock protein HSP 90-alphaHomo sapiens (human)
chaperone-mediated protein complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of cardiac muscle contractionHeat shock protein HSP 90-alphaHomo sapiens (human)
chaperone-mediated autophagyHeat shock protein HSP 90-alphaHomo sapiens (human)
cellular response to virusHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of tau-protein kinase activityHeat shock protein HSP 90-alphaHomo sapiens (human)
telomerase holoenzyme complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
cellular response to heatHeat shock protein HSP 90-alphaHomo sapiens (human)
protein foldingHeat shock protein HSP 90-alphaHomo sapiens (human)
telomere maintenance via telomeraseHeat shock protein HSP 90-betaHomo sapiens (human)
placenta developmentHeat shock protein HSP 90-betaHomo sapiens (human)
response to unfolded proteinHeat shock protein HSP 90-betaHomo sapiens (human)
virion attachment to host cellHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of protein ubiquitinationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of protein localizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of apoptotic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of cell differentiationHeat shock protein HSP 90-betaHomo sapiens (human)
chaperone-mediated protein complex assemblyHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of cell cycleHeat shock protein HSP 90-betaHomo sapiens (human)
chaperone-mediated protein foldingHeat shock protein HSP 90-betaHomo sapiens (human)
cellular response to interleukin-4Heat shock protein HSP 90-betaHomo sapiens (human)
supramolecular fiber organizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of proteasomal protein catabolic processHeat shock protein HSP 90-betaHomo sapiens (human)
telomerase holoenzyme complex assemblyHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of protein localization to cell surfaceHeat shock protein HSP 90-betaHomo sapiens (human)
cellular response to heatHeat shock protein HSP 90-betaHomo sapiens (human)
protein foldingHeat shock protein HSP 90-betaHomo sapiens (human)
protein stabilizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (120)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Mus musculus (house mouse)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine oxidase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
iron ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdenum ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
protein homodimerization activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
FAD bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
UTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
CTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
RNA bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
mRNA bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
GTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP hydrolysis activityHeat shock protein HSP 90-alphaHomo sapiens (human)
sulfonylurea receptor bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein phosphatase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
MHC class II protein complex bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
nitric-oxide synthase regulator activityHeat shock protein HSP 90-alphaHomo sapiens (human)
TPR domain bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
dATP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
identical protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein homodimerization activityHeat shock protein HSP 90-alphaHomo sapiens (human)
histone deacetylase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
transmembrane transporter bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
tau protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
GTPase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
Rho GDP-dissociation inhibitor bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
DNA polymerase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
scaffold protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
disordered domain specific bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock protein HSP 90-alphaHomo sapiens (human)
protein tyrosine kinase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
unfolded protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
RNA bindingHeat shock protein HSP 90-betaHomo sapiens (human)
double-stranded RNA bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP hydrolysis activityHeat shock protein HSP 90-betaHomo sapiens (human)
protein kinase regulator activityHeat shock protein HSP 90-betaHomo sapiens (human)
kinase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein kinase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
MHC class II protein complex bindingHeat shock protein HSP 90-betaHomo sapiens (human)
nitric-oxide synthase regulator activityHeat shock protein HSP 90-betaHomo sapiens (human)
TPR domain bindingHeat shock protein HSP 90-betaHomo sapiens (human)
heat shock protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
peptide bindingHeat shock protein HSP 90-betaHomo sapiens (human)
identical protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein homodimerization activityHeat shock protein HSP 90-betaHomo sapiens (human)
histone deacetylase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP-dependent protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein folding chaperoneHeat shock protein HSP 90-betaHomo sapiens (human)
cadherin bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein dimerization activityHeat shock protein HSP 90-betaHomo sapiens (human)
tau protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
DNA polymerase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
disordered domain specific bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock protein HSP 90-betaHomo sapiens (human)
receptor ligand inhibitor activityHeat shock protein HSP 90-betaHomo sapiens (human)
histone methyltransferase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
unfolded protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (65)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Mus musculus (house mouse)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseBos taurus (cattle)
peroxisomeXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine dehydrogenase complexXanthine dehydrogenase/oxidaseBos taurus (cattle)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
mitochondrionHeat shock protein HSP 90-alphaHomo sapiens (human)
cytosolHeat shock protein HSP 90-alphaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
cell surfaceHeat shock protein HSP 90-alphaHomo sapiens (human)
membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
basolateral plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
apical plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
brush border membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
secretory granule lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
melanosomeHeat shock protein HSP 90-alphaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-alphaHomo sapiens (human)
lysosomal lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
dendritic growth coneHeat shock protein HSP 90-alphaHomo sapiens (human)
axonal growth coneHeat shock protein HSP 90-alphaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
collagen-containing extracellular matrixHeat shock protein HSP 90-alphaHomo sapiens (human)
extracellular exosomeHeat shock protein HSP 90-alphaHomo sapiens (human)
endocytic vesicle lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
sperm mitochondrial sheathHeat shock protein HSP 90-alphaHomo sapiens (human)
sperm plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
protein-containing complexHeat shock protein HSP 90-alphaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-alphaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
myelin sheathHeat shock protein HSP 90-alphaHomo sapiens (human)
cytosolHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
COP9 signalosomeHeat shock protein HSP 90-betaHomo sapiens (human)
protein folding chaperone complexHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular regionHeat shock protein HSP 90-betaHomo sapiens (human)
nucleusHeat shock protein HSP 90-betaHomo sapiens (human)
nucleoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
mitochondrionHeat shock protein HSP 90-betaHomo sapiens (human)
cytosolHeat shock protein HSP 90-betaHomo sapiens (human)
cell surfaceHeat shock protein HSP 90-betaHomo sapiens (human)
membraneHeat shock protein HSP 90-betaHomo sapiens (human)
secretory granule lumenHeat shock protein HSP 90-betaHomo sapiens (human)
melanosomeHeat shock protein HSP 90-betaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-betaHomo sapiens (human)
dendritic growth coneHeat shock protein HSP 90-betaHomo sapiens (human)
axonal growth coneHeat shock protein HSP 90-betaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular exosomeHeat shock protein HSP 90-betaHomo sapiens (human)
dynein axonemal particleHeat shock protein HSP 90-betaHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock protein HSP 90-betaHomo sapiens (human)
protein-containing complexHeat shock protein HSP 90-betaHomo sapiens (human)
aryl hydrocarbon receptor complexHeat shock protein HSP 90-betaHomo sapiens (human)
HSP90-CDC37 chaperone complexHeat shock protein HSP 90-betaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-betaHomo sapiens (human)
cytosolHeat shock protein HSP 90-betaHomo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)
cytoplasmic vesicle membraneSolute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (412)

Assay IDTitleYearJournalArticle
AID453021Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID1239598Disruption of biofilm formation in Staphylococcus aureus 8325-4 after 24 hrs by microtiter plate assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Hydnocarpin-Type Flavonolignans: Semisynthesis and Inhibitory Effects on Staphylococcus aureus Biofilm Formation.
AID621928Cytotoxicity against HUVEC by LDH release assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID187636Tested for release of glutamic pyruvic transaminase (GPT) from CCl4 induced toxicity in primary cultures of rat hepatocytes at 50 uM concentration2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Hepatoprotective pyrrole derivatives of Lycium chinense fruits.
AID376573Hepatoprotective activity in Wistar rat CCL4-damaged hepatocyte assessed as blockade of glutamic pyruvic transaminase release at 100 uM relative to control2000Journal of natural products, Jul, Volume: 63, Issue:7
Hepatoprotective diastereomeric lignans from Saururus chinensis herbs.
AID1782119Aqueous solubility of the compound2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release.
AID1428663Antiradical activity assessed as gallic acid equivalents of Foline-Ciocalteu reagent reducing capacity at 1 mM preincubated for 5 mins followed by Na2CO3 addition measured after 90 mins2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID595296Inhibition of Hsp90-dependent maturation of [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate at 2 mM by anti-His-tag pull down assay2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID453019Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 10 uM after 20 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID609842Antioxidant activity in rat immortalized Rat1 cells assessed as inhibition of hydrogen peroxide-induced reactive oxygen species production by measuring conversion of 2',7'-dichlorofluorescin diacetate into 2',7'-dichlorofluorescein at 30 uM treated 48 hrs2011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
New C-23 modified of silybin and 2,3-dehydrosilybin: synthesis and preliminary evaluation of antioxidant properties.
AID768893Inhibition of human thrombin assessed as equilibrium association constant at 50 to 1000 uM by BIAcore analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID1428426Antioxidant activity against tert-butyl hydroperoxide-induced lipoperoxidation in rat liver microsomal membranes incubated for 60 mins by TBARS assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID768907Inhibition of human thrombin assessed as inhibition of fibrinogen alpha-polymer formation at 250 uM after 15 mins by SDS-PAGE analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID1382202Inhibition of amyloid beta 42 (unknown origin) expressed in Escherichia coli BL21 (DE3) aggregation at 10 uM incubated for overnight by Th-S fluorescence staining based UV-Vis spectrophotometer (Rvb = 0 +/- 1%)2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID1428665Antioxidant activity assessed as trolox equivalent of ABTS radical scavenging activity at 100 uM measured at >= 5 mins2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID424723Ratio of kcat to km for bovine xanthine oxidase at 25 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID768929Inhibition of human thrombin amidolytic activity using D-Phe-Pip-Arg-pNA as substrate preincubated for 10 mins followed by substrate addition measured every 12 secs for 10 mins by spectrophotometric analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID359492Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 25 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1382223Neurotoxicity against mouse HT22 cells assessed as decrease in cell viability at 25 uM using 1:1 test compound to cinnamic acid ratio measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID681195TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Silybin: 50 uM) in BCRP-expressing MCF-7 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID1616107Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID464224Cytotoxicity against MDCK cells after 2 hrs by MTT assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Antioxidant and antiviral activities of silybin fatty acid conjugates.
AID1382208Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID767621Cytotoxicity against human HT1080 cells2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID424719Activity at bovine xanthine oxidase at 25 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID716426Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID1428422Antiradical activity assessed as gallic acid equivalents of Foline-Ciocalteu reagent reducing capacity at 1 mM preincubated for 5 mins followed by Na2CO3 addition measured after 90 mins2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID458992Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID768888Inhibition of urokinase amidolytic activity (unknown origin)2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID595300Antiproliferative activity against estrogen receptor-deficient human SKBR3 cells expressing HER22011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID458986Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID424724Ratio of kcat to km for bovine xanthine oxidase at 50 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID453014Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 30 uM after 44 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID1172634Inhibition of xanthine oxidase in human MKN28 cells assessed as inhibition of xanthine oxidase-induced cell damage by measuring cell viability at 10 to 200 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
New silibinin glyco-conjugates: synthesis and evaluation of antioxidant properties.
AID1603425Inhibition of monophenolase activity of mushroom tyrosinase assessed as reduction in dopachrome formation using L-Tyrosine substrate by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID400930Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay relative to control2004Journal of natural products, Apr, Volume: 67, Issue:4
Structures of new sesquiterpenes and hepatoprotective constituents from the Egyptian herbal medicine Cyperus longus.
AID458989Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 10 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID595301Antiproliferative activity against human MCF7 cells expressing estrogen receptor2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID1325297Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID595267Inhibition of Hsp90 in human MCF7 cells assessed as Raf degradation at 50 to 1000 uM by Western blot analysis2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID359151Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes assessed as cell viability at 50 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to normal hep2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID1586111Antiviral activity against HCV JFH-1 infected in human Huh7.5.1 cells assessed as reduction in NS3/NS5A expression by Western blot analysis2018Journal of natural products, 12-28, Volume: 81, Issue:12
1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.
AID1306222Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 3 days by WST-1 assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
3-O-Alkyl-2,3-dehydrosilibinins: Two synthetic approaches and in vitro effects toward prostate cancer cells.
AID453012Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 3 uM after 44 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID1382203Inhibition of amyloid beta 42 (unknown origin) expressed in Escherichia coli BL21 (DE3) aggregation at 100 uM incubated for overnight by Th-S fluorescence staining based UV-Vis spectrophotometer (Rvb = 0 +/- 4.4%)2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID1428677Antioxidant activity against tert-butyl hydroperoxide-induced lipoperoxidation in rat liver microsomal membranes preincubated for 10 mins followed by tert-butyl hydroperoxide addition measured after 60 mins in presence of L-ascorbic acid by TBARS assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID1325291Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID1586112Selectivity index, ratio of CC50 for human Huh7.5.1 cells to IC50 for HCV JFH1 infected in human Huh7.5.1 cells2018Journal of natural products, 12-28, Volume: 81, Issue:12
1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.
AID359485Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 12.5 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID400928Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 30 uM after 44 hrs by MTT assay relative to control2004Journal of natural products, Apr, Volume: 67, Issue:4
Structures of new sesquiterpenes and hepatoprotective constituents from the Egyptian herbal medicine Cyperus longus.
AID592714Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID626962Cytotoxicity against human embryo L02 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Bioactive dammarane-type saponins from Operculina turpethum.
AID1782120Antioxidant activity assessed as DPPH radical scavenging activity measured for 60 mins by spectrophotometric analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release.
AID458987Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID1239596Inhibition of biofilm formation in Staphylococcus aureus 8325-4 after 24 hrs by microtiter plate assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Hydnocarpin-Type Flavonolignans: Semisynthesis and Inhibitory Effects on Staphylococcus aureus Biofilm Formation.
AID401475Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID609843Octanol-water partition coefficient, log P of the compound at pH 7.4 by stir-flask method2011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
New C-23 modified of silybin and 2,3-dehydrosilybin: synthesis and preliminary evaluation of antioxidant properties.
AID379988Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 25 uM after 18 hrs by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
Quadranosides I-V, new triterpene glucosides from the seeds of Combretum quadrangulare.
AID403198Antihepatotoxic activity against CCl4-induced cytotoxicity in rat hepatocytes assessed as blockade of glutamic pyruvic transaminase release at 25 uM by Reitman-Frankel method relative to control1997Journal of natural products, Mar, Volume: 60, Issue:3
New antihepatotoxic cerebroside from Lycium chinense fruits.
AID449301Inhibition of rat liver xanthine oxidase after 2 hrs by spectrophotometry2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives.
AID424739Inhibition of bovine xanthine oxidase assessed as decrease in production of superoxide at 50 uM relative to control2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID1603439Binding affinity to mushroom tyrosinase assessed as Stern-Volmer quenching constant by fluorescence spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID595265Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation at 50 to 1000 uM by Western blot analysis2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID1428673Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins in presence of L-ascorbic acid by spectrophotometric method2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID401473Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs relative to control
AID592725Cytotoxicity against rat HSC-T6 cell up to 300 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID450967Inhibition of FeSO4-induced lipid peroxidation in Sprague-Dawley rat liver homogenate assessed as decrease in malondialdehyde level after 1 hr by TBA assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Preparation of C-23 esterified silybin derivatives and evaluation of their lipid peroxidation inhibitory and DNA protective properties.
AID359491Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 12.5 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1382206Inhibition of tau (unknown origin) aggregation expressed in Escherichia coli (DE3) at 100 uM incubated for overnight by Th-S fluorescence staining based UV-Vis spectrophotometer (Rvb = 0.0 +/- 2.4%)2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID768909Inhibition of human thrombin assessed as inhibition of fibrinogen alpha-polymer formation at 250 uM after 5 mins by SDS-PAGE analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID716442Hepatoprotective against tacrine-induced toxicity in Wistar rat liver assessed as increase in ratio of reduced/oxidised glutathione at 6 uM/100 gram of body weight, ip after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID589150Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID233143Change in Fmax was determined2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein.
AID1382193Induction of rat PC12 cells differentiation assessed as neurite outgrowth at 10 uM after 24 hrs relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1603426Mixed type inhibition of monophenolase activity of mushroom tyrosinase assessed as reduction in dopachrome formation using L-Tyrosine substrate by UV-Vis spectrophotometry based Dixon plot analysis2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID401471Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs relative to control
AID1277234Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
AID1461954Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay
AID977603pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1603433Inhibition of diphenolase activity of mushroom tyrosinase assessed as inhibition constant for free enzyme-inhibitor complex by measuring reduction in dopachrome formation using L-DOPA substrate by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID595302Inhibition of Hsp90/Cdc37 interaction with [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate at 2 mM by Western blot analysis2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID1277233Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
AID716440Hepatotoxicity against Wistar rat assessed as increase in tissue content of oxidised glutathione at 6 uM/100 gram of body weight, ip after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID595318Inhibition of Hsp90-dependent activation of [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate at 2 mM by anti-His-tag pull down assay2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID401472Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs relative to control
AID768900Inhibition of human thrombin assessed as decrease in platelet aggregation at 1000 uM preincubated for 10 mins measured for 10 mins by dual channel chrono-log aggregometric analysis relative to control2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID424733Inhibition of bovine xanthine oxidase assessed as reduction in xanthine turnover at 50 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID424725Ratio of kcat to km for bovine xanthine oxidase at 25 uM preincubated for 10 mins2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID424732Inhibition of bovine xanthine oxidase assessed as reduction in xanthine turnover at 25 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID359682Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID379989Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM after 18 hrs by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
Quadranosides I-V, new triterpene glucosides from the seeds of Combretum quadrangulare.
AID427868Hepatoprotective activity against nitrofurantoin-induced cytotoxicity in human HepG2 cells after 2 hrs by MTT assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Cycloartane triterpenoids from Kleinhovia hospita.
AID359155Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes at 25 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to control2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID1382194Antioxidant activity assessed as ferric ion reduction by measuring FeSO4 equivalents reducing Fe3+-TPTZ to Fe2+-TPTZ measured every 15 secs for 4 mins by FRAP assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID595268Inhibition of Hsp90 in human MCF7 cells assessed as Akt degradation at 50 to 1000 uM by Western blot analysis2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID977600pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID768889Inhibition of trypsin amidolytic activity (unknown origin)2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID187634Tested for release of glutamic pyruvic transaminase (GPT) from CCl4 induced toxicity in primary cultures of rat hepatocytes at 1 uM concentration2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Hepatoprotective pyrrole derivatives of Lycium chinense fruits.
AID1603428Inhibition of monophenolase activity of mushroom tyrosinase assessed as inhibition constant for free enzyme-inhibitor complex by measuring reduction in dopachrome formation using L-Tyrosine substrate by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID1325300Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 100 uM after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID401476Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs
AID1382209Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID424729Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 50 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID140148Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 0 uM2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Anastatins A and B, new skeletal flavonoids with hepatoprotective activities from the desert plant Anastatica hierochuntica.
AID621933Antiangiogenic activity in HUVEC assessed as inhibition of tube formation after 24 hrs by Matrigel assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID592721Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID424721Activity at bovine xanthine oxidase at 25 uM preincubated for 10 mins2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID1382197Neurotoxicity against mouse HT22 cells assessed as decrease in cell viability at 25 uM measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID359152Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes assessed as cell viability at 25 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to normal hep2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID400929Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 uM after 44 hrs by MTT assay relative to control2004Journal of natural products, Apr, Volume: 67, Issue:4
Structures of new sesquiterpenes and hepatoprotective constituents from the Egyptian herbal medicine Cyperus longus.
AID450964Antioxidant activity assessed as DPPH radical scavenging activity at 100 ug/mL after 30 mins2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Preparation of C-23 esterified silybin derivatives and evaluation of their lipid peroxidation inhibitory and DNA protective properties.
AID359154Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes at 50 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to control2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID1586110Cytotoxicity against human Huh7.5.1 cells after 72 hrs by ATPlite assay2018Journal of natural products, 12-28, Volume: 81, Issue:12
1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.
AID1428671Antiradical activity assessed as gallic acid equivalents of Foline-Ciocalteu reagent reducing capacity at 1 mM preincubated for 5 mins followed by Na2CO3 addition measured after 90 mins in presence of L-ascorbic acid2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID450965Antioxidant activity assessed as superoxide anion scavenging activity at 100 ug/mL after 5 mins by NBT reduction assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Preparation of C-23 esterified silybin derivatives and evaluation of their lipid peroxidation inhibitory and DNA protective properties.
AID1428424Antioxidant activity assessed as trolox equivalent of ABTS radical scavenging activity at 100 uM incubated for >= 5 mins2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID626964Cytoprotective activity in human embryo L02 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 6.25 ug/ml treated for 1 hr prior to D-galactosamine challenge measured after 48 hrs by MTT assay relative to control2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Bioactive dammarane-type saponins from Operculina turpethum.
AID1364958Antiviral activity against Chikungunya virus infected in African green monkey Vero cells after 72 hrs by MTT dye-based assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID140151Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 30 uM2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Anastatins A and B, new skeletal flavonoids with hepatoprotective activities from the desert plant Anastatica hierochuntica.
AID1325299Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 50 uM after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID458985Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 30 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID450966Antioxidant activity assessed as ferrous ion chelating activity after 30 mins by spectrophotometry2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Preparation of C-23 esterified silybin derivatives and evaluation of their lipid peroxidation inhibitory and DNA protective properties.
AID1172632Antioxidant activity assessed as DPPH radical scavenging activity after 10 mins2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
New silibinin glyco-conjugates: synthesis and evaluation of antioxidant properties.
AID657573Antioxidant activity assessed as DPPH radical scavenging activity by densitometric analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Bioconversion of silybin to phase I and II microbial metabolites with retained antioxidant activity.
AID1277235Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
AID359153Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes at 100 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to control2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID458988Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 3 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID400607Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression at 10 uM after 18 hrs measured as microunits of tissue factor/10'5 cells1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID1239597Toxicity in Staphylococcus aureus 8325-4 assessed as inhibition of bacterial growth2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Hydnocarpin-Type Flavonolignans: Semisynthesis and Inhibitory Effects on Staphylococcus aureus Biofilm Formation.
AID1428660Electro-oxidation activity at glassy carbon electrode in pH 5 acetate buffer at 50 uM by square-wave voltammetry2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID379991Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 200 uM after 18 hrs by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
Quadranosides I-V, new triterpene glucosides from the seeds of Combretum quadrangulare.
AID1603434Inhibition of diphenolase activity of mushroom tyrosinase assessed as inhibition constant for enzyme-substrate-inhibitor complex by measuring reduction in dopachrome formation using L-DOPA substrate by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID1306221Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 3 days by WST-1 assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
3-O-Alkyl-2,3-dehydrosilibinins: Two synthetic approaches and in vitro effects toward prostate cancer cells.
AID424718Activity at bovine xanthine oxidase at 10 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID400926Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 3 uM after 44 hrs by MTT assay relative to control2004Journal of natural products, Apr, Volume: 67, Issue:4
Structures of new sesquiterpenes and hepatoprotective constituents from the Egyptian herbal medicine Cyperus longus.
AID1603431Mixed type inhibition of diphenolase activity of mushroom tyrosinase assessed as reduction in dopachrome formation using L-DOPA substrate by UV-Vis spectrophotometry based Dixon plot analysis2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID1603435Inhibition of monophenolase activity of mushroom tyrosinase assessed as increase in lag period of monophenolase for oxidation of L-tyrosine substrate at 0.5 to 16 uM by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1428666Antioxidant activity against tert-butyl hydroperoxide-induced lipoperoxidation in rat liver microsomal membranes preincubated for 10 mins followed by tert-butyl hydroperoxide addition measured after 60 mins by TBARS assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID1428681Cytoprotective activity against tert-butyl hydroperoxide-induced toxicity in human HepG2 cells assessed as cell viability at 5 uM pretreated for 1 hr followed by tert-butyl hydroperoxide addition for 3 hrs by MTT assay (Rvb = 16%)2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID1325298Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 10 uM after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID1603429Inhibition of monophenolase activity of mushroom tyrosinase assessed as inhibition constant for enzyme-substrate-inhibitor complex by measuring reduction in dopachrome formation using L-Tyrosine substrate by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID716210Neurotoxicity in mouse hippocampal HT22 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID589119Mechanism based inhibition of human cytochrome P450 3A4 measured by BFC hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1382224Neurotoxicity against mouse HT22 cells assessed as decrease in cell viability at 25 uM using 1:1 test compound to ferulic acid ratio measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID354703Antihepatotoxic activity against CCl4-induced toxicity in rat hepatocytes assessed as effect on SDH activity at 5 uM by Geralch method relative to control1996Journal of natural products, Mar, Volume: 59, Issue:3
New bioactive cerebrosides from Arisaema amurense.
AID779150Inhibition of Wnt/beta-catenin signaling pathway in human HEK293 cells at 20 uM after 24 hrs by dual luciferase reporter gene assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells.
AID424720Activity at bovine xanthine oxidase at 50 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID359486Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 25 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID464225Antiviral activity against Influenza A virus (A/PR8/34(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Antioxidant and antiviral activities of silybin fatty acid conjugates.
AID768895Inhibition of human thrombin assessed as response unit at 1000 uM by BIAcore analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID453020Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 30 uM after 20 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID1382225Neuroprotective activity against glutamate-induced mouse HT22 cells assessed as increase in cell survival at 1 to 25 uM cotreated with glutamate measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID1461955Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay
AID716425Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID424738Ratio of kcat to km for bovine xanthine oxidase at 25 uM preincubated for 10 mins relative to control2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID621925Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID464222Antioxidant activity in Wistar rat liver microsomes assessed as inhibition of lipid peroxidation after 1 hr by thiobarbiturate color reaction2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Antioxidant and antiviral activities of silybin fatty acid conjugates.
AID187635Tested for release of glutamic pyruvic transaminase (GPT) from CCl4 induced toxicity in primary cultures of rat hepatocytes at 10 uM concentration2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Hepatoprotective pyrrole derivatives of Lycium chinense fruits.
AID359487Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID453017Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 1 uM after 20 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID768887Inhibition of human thrombin assessed as inhibition of fibrinogen polymerization at 1000 uM preincubated for 10 mins followed by fibrionogen addition measured for 20 mins2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID400927Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 uM after 44 hrs by MTT assay relative to control2004Journal of natural products, Apr, Volume: 67, Issue:4
Structures of new sesquiterpenes and hepatoprotective constituents from the Egyptian herbal medicine Cyperus longus.
AID359493Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID403199Antihepatotoxic activity against CCl4-induced cytotoxicity in rat hepatocytes assessed as blockade of sorbitol dehydrogenase release at 25 uM by modified Gerlach method relative to control1997Journal of natural products, Mar, Volume: 60, Issue:3
New antihepatotoxic cerebroside from Lycium chinense fruits.
AID595266Inhibition of Hsp90 in human MCF7 cells assessed as Hsp90 degradation at 50 to 1000 uM by Western blot analysis2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID1428675Antioxidant activity assessed as trolox equivalent of ABTS radical scavenging activity at 100 uM measured at >= 5 mins in presence of L-ascorbic acid2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID1428664Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by spectrophotometric method2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID424727Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 10 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID449291Inhibition of lipid peroxidation in Sprague-Dawley rat liver homogenate assessed as malondialdehyde formation after 1 hr by TBARS assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives.
AID453015Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 uM after 44 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID1428682Cytotoxicity against human HepG2 cells assessed as reduction in cell viability up to 10 uM after 4 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID377041Hepatoprotective activity against H2O2-induced hepatotoxicity in Wistar rat hepatocytes assessed as reduction in glutamic pyruvate transaminase release at 100 uM after 1 hr relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Two new hepatoprotective stilbene glycosides from Acer mono leaves.
AID977601Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID768910Inhibition of human thrombin assessed as inhibition of fibrinogen gamma-gamma chain formation at 250 uM after 5 mins by SDS-PAGE analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID359497Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 25 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1603437Inhibition of monophenolase activity of mushroom tyrosinase assessed as reduction in steady state rate monophenolase activity for oxidation of L-tyrosine substrate at 0.5 to 16 uM by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID595270Inhibition of Hsp90-dependent activation of [35S]-labeled His-tagged eIF2alpha in rabbit reticulocyte lysate by anti-His-tag pull down assay2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID354702Antihepatotoxic activity against CCl4-induced toxicity in rat hepatocytes assessed as effect on GPT activity at 5 uM by Reitman-Fankel method relative to control1996Journal of natural products, Mar, Volume: 59, Issue:3
New bioactive cerebrosides from Arisaema amurense.
AID716204Inhibition of electric eel AChE at 100 uM by colorimetric Ellman assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID150738Compound was tested for the binding affinity towards recombinant NBD2 C-terminal cytotoxic nucleotide-binding domain of mouse P-Glycoprotein2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein.
AID592715Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID1382205Inhibition of tau (unknown origin) aggregation expressed in Escherichia coli (DE3) at 10 uM incubated for overnight by Th-S fluorescence staining based UV-Vis spectrophotometer (Rvb = 0.0 +/- 1.4%)2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID589083Mechanism based inhibition of human cytochrome P450 2C9 measured by 7-EFC O-deethylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1172633Toxicity in human MKN28 cells assessed as cell viability at 10 to 200 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
New silibinin glyco-conjugates: synthesis and evaluation of antioxidant properties.
AID681180TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Silybin: 50 uM) in BCRP-expressing NCI-H460 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID1428425Partition coefficient, logP of the compound in octan-1-ol and phosphate buffer at pH 7.4 at 25 degC after 2 hrs by UV-vis spectrometer2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID621930Antiangiogenic activity in HUVEC assessed as inhibition of cell migration after 16 to 20 hrs by wound healing migration assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID977604Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID140150Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 3 uM2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Anastatins A and B, new skeletal flavonoids with hepatoprotective activities from the desert plant Anastatica hierochuntica.
AID464223Antioxidant activity assessed as DPPH radical scavenging activity for 10 mins2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Antioxidant and antiviral activities of silybin fatty acid conjugates.
AID453018Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity at 3 uM after 20 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID716443Hepatoprotective activity against tacrine-induced toxicity in Wistar rat liver assessed as decrease in tissue content of TBARS at 2 uM/100 gram of body weight, ip after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID716439Hepatotoxicity against Wistar rat assessed as increase in tissue content of oxidised glutathione at 2 uM/100 gram of body weight after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID621929Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID359156Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID1428678Cytoprotective activity against tert-butyl hydroperoxide-induced toxicity in human HepG2 cells assessed as cell viability at 5 uM pretreated for 1 hr followed by co-treatment with tert-butyl hydroperoxide for 3 hrs by MTT assay (Rvb = 22%)2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID768899Inhibition of human thrombin assessed as decrease in platelet aggregation at 25 to 250 uM preincubated for 10 mins measured for 10 mins by dual channel chrono-log aggregometric analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID1603440Binding affinity to mushroom tyrosinase assessed as binding constant by fluorescence spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID626966Cytoprotective activity in human embryo L02 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 1.56 ug/ml treated for 1 hr prior to D-galactosamine challenge measured after 48 hrs by MTT assay relative to control2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Bioactive dammarane-type saponins from Operculina turpethum.
AID458990Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 30 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID592713Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity at 100 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID1306220Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 3 days by WST-1 assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
3-O-Alkyl-2,3-dehydrosilibinins: Two synthetic approaches and in vitro effects toward prostate cancer cells.
AID592724Hepatoprotective activity in human HepG2 cells assessed as protection against cell damage after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID424730Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 25 uM preincubated for 10 mins2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID592722Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID359150Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes assessed as cell viability at 100 uM treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay relative to normal he2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity.
AID716441Hepatoprotective against tacrine-induced toxicity in Wistar rat liver assessed as increase in ratio of reduced/oxidised glutathione at 2 uM/100 gram of body weight, ip after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID609844Cytotoxicity against rat immortalized Rat1 cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
New C-23 modified of silybin and 2,3-dehydrosilybin: synthesis and preliminary evaluation of antioxidant properties.
AID1382227Neuroprotective activity against glutamate-induced mouse HT22 cells assessed as increase in cell survival at 1 to 25 uM using 1:1 test compound to ferulic acid ratio cotreated with glutamate measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID768894Inhibition of human thrombin assessed as equilibrium dissociation constant at 50 to 1000 uM by BIAcore analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID458984Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID424731Inhibition of bovine xanthine oxidase assessed as reduction in xanthine turnover at 10 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID716205Inhibition of horse AChE at 100 uM by colorimetric Ellman assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID359496Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 12.5 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID768892Competitive inhibition of human thrombin using D-Phe-Pip-Arg-pNA as substrate preincubated for 10 mins followed by substrate addition measured every 12 secs for 10 mins by Lineweaver-Burk plot analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID359488Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID424728Inhibition of bovine xanthine oxidase assessed as reduction of cytochrome c at 20 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID1382228Antioxidant activity assessed as reduction of Fe3+-TPTZ to Fe2+-TPTZ using equimolar mixture of test compound and cinnamic acid measured every 15 secs for 4 mins by FRAP assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID621932Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 75 uM after 6 hrs by Matrigel assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID768890Inhibition of thrombin (unknown origin) assessed as hydrolysis of N-benzoyl-phenylalanylvalyl-arginine-paranitroanilide2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID1428679Cytoprotective activity against tert-butyl hydroperoxide-induced decrease in cell viability in human HepG2 cells at 5 uM pretreated for 1 hr followed by co-treatment with tert-butyl hydroperoxide for 3 hrs in presence of L-ascorbic acid by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel flavonolignan hybrid antioxidants: From enzymatic preparation to molecular rationalization.
AID716424Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID609872Cytotoxicity against rat immortalized Rat1 cells assessed as reduction of cell viability at 30 uM after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
New C-23 modified of silybin and 2,3-dehydrosilybin: synthesis and preliminary evaluation of antioxidant properties.
AID768908Inhibition of human thrombin assessed as inhibition of fibrinogen gamma-gamma chain formation at 250 uM after 15 mins by SDS-PAGE analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID1428423Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1616108Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID1461956Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay
AID768927Inhibition of human thrombin assessed as inhibition of fibrinogen polymerization preincubated for 10 mins followed by fibrionogen addition measured for 20 mins2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID401474Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs
AID379990Hepatoprotective activity against mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cell death at 100 uM after 18 hrs by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
Quadranosides I-V, new triterpene glucosides from the seeds of Combretum quadrangulare.
AID424722Ratio of kcat to km for bovine xanthine oxidase at 10 uM2009Journal of natural products, Apr, Volume: 72, Issue:4
Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin.
AID626965Cytoprotective activity in human embryo L02 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 3.13 ug/ml treated for 1 hr prior to D-galactosamine challenge measured after 48 hrs by MTT assay relative to control2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Bioactive dammarane-type saponins from Operculina turpethum.
AID1382217Antioxidant activity assessed as reduction of Fe3+-TPTZ to Fe2+-TPTZ using 1:1 test compound to ferulic acid ratio measured every 15 secs for 4 mins by FRAP assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.
AID140149Inhibitory activity derived from Anastatica hierochuntica on D-Gal-induced cytotoxicity in primary cultured mouse hepatocytes at a concentration of 10 uM2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Anastatins A and B, new skeletal flavonoids with hepatoprotective activities from the desert plant Anastatica hierochuntica.
AID716445Antiamnesic activity against scopolamine-induced cognitive impairment in Wistar rat assessed as reduction in number of error made at 2 umol/100 g body weight after 20 to 120 mins by eight arm radial maze test2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID449302Inhibition of rat liver xanthine oxidase at 75 uM after 2 hrs by spectrophotometry2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives.
AID716211Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID458983Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 3 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID1603430Inhibition of diphenolase activity of mushroom tyrosinase assessed as reduction in dopachrome formation using L-DOPA substrate by UV-Vis spectrophotometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle).
AID458991Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity at 100 ug/mL after 44 hrs by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Acylated phenylethanoid oligoglycosides with hepatoprotective activity from the desert plant Cistanche tubulosa.
AID453013Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 uM after 44 hrs by MTT assay relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides.
AID1428427Cytotoxicity against human RPE1 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1214758Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake at 10 uM after 3 mins by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462360Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 1 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1129260Agonist activity at human PPAR-gamma expressed in HEK293 cells at 30 ug/ml after 18 hrs by luciferase reporter gene assay relative to control2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma.
AID755106Inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate after 30 mins2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
AID1333023Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1333029Cytotoxicity against human LNCAP cells assessed as cell growth inhibition at 200 uM after 48 hrs by MTT assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID462336Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 1 uM after 72 hrs2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1333028Cytotoxicity against human ARCaPM cells assessed as cell growth inhibition at 200 uM after 48 hrs by MTT assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214762Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462333Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 30 uM after 72 hrs2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID462362Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 10 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1333031Cytotoxicity against human DU145 cells assessed as cell growth inhibition at 200 uM after 48 hrs by MTT assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID755104Inhibition of UGT in human liver microsomes using 4-methylumbelliferone as substrate after 10 mins by fluorescence analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
AID462335Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 3 uM after 72 hrs2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1254734Terminal half life in orally dosed human by LC-MS/MS method2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Development of Safe and Effective Botanical Dietary Supplements.
AID201240Minimum inhibitory concentration, that inhibits growth of Staphylococcus aureus in the presence of subinhibitory (30 ug/mL) Berberine2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: structure-activity relationships.
AID462357Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 3 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1214760Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake at 10 uM after 3 mins by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1869054Activation of chymotrypsin-like activity of yeast 20s proteasome using suc-LLVY-AMC as flurogenic substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence assay2022Bioorganic & medicinal chemistry, 07-15, Volume: 66Silybins are stereospecific regulators of the 20S proteasome.
AID1428434Cytotoxicity against human MCF7 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID462345Inhibition of mushroom tyrosinase at 3 uM2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID462343Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1333034Antitumor activity against wild type B6/129PF2 mouse lung tumor assessed reduction in urethane-induced tumor growth at 742 mg/kg, po administered via gavage for 5 days per week for 18 weeks starting from 8 weeks after urethane injection measured 25 weeks 2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214779Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg to IC50 for OATP1B1 (unknown origin) expressed in HEK293 cells2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1214773Protein binding in rat2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1869055Activation of trypsin-like activity of yeast 20s proteasome using Z-LLG-AMC as flurogenic substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence assay2022Bioorganic & medicinal chemistry, 07-15, Volume: 66Silybins are stereospecific regulators of the 20S proteasome.
AID462356Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 1 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID462341Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 10 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID462365Inhibition of ERK1/2 phosphorylation in mouse B16-4A5 cells at 100 uM in presence of 1 mM theophylline after 72 hrs by immunoblot2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1586110Cytotoxicity against human Huh7.5.1 cells after 72 hrs by ATPlite assay2018Journal of natural products, 12-28, Volume: 81, Issue:12
1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.
AID1869056Activation of PGPHL-peptidase activity of yeast 20s proteasome using Ac-RLR-AMC as flurogenic substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence assay2022Bioorganic & medicinal chemistry, 07-15, Volume: 66Silybins are stereospecific regulators of the 20S proteasome.
AID462346Inhibition of mushroom tyrosinase at 10 uM2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1214783Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg to IC50 for OATP2B1 (unknown origin) expressed in HEK293 cells2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1214777fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462354Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 10 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID462347Inhibition of mushroom tyrosinase at 30 uM2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID621928Cytotoxicity against HUVEC by LDH release assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID1759237Inhibition of laminin deposition in human LX2 cells2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis and anti-fibrotic effects of santamarin derivatives as cytotoxic agents against hepatic stellate cell line LX2.
AID1333039Photocytotoxicity against mouse JB6 cells assessed as increase in cleaved caspase-3 level pretreated for 24 hrs followed by 100 mJ/cm2 UV-B irradiation by Western blot method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214770Inhibition of OATP-mediated [3H]estradiol-17beta-glucuronide uptake in sandwich-cultured human hepatocytes at 100 uM after 8 days by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1428431Cytotoxicity against human K562 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID462344Inhibition of mushroom tyrosinase at 1 uM2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID462350Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 3 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1214780Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg to IC50 for OATP1B3 (unknown origin) expressed in HEK293 cells2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1759233Cytotoxicity against human LX2 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis and anti-fibrotic effects of santamarin derivatives as cytotoxic agents against hepatic stellate cell line LX2.
AID1214763Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake after 3 mins by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1586112Selectivity index, ratio of CC50 for human Huh7.5.1 cells to IC50 for HCV JFH1 infected in human Huh7.5.1 cells2018Journal of natural products, 12-28, Volume: 81, Issue:12
1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.
AID462340Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 3 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1333022Downregulation of telomerase expression in human T47D cells after 72 hrs in presence of curcumin by SYBR green-dye based RT-PCR analysis2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1333026Drug excretion in bile-duct cannulated Sprague-Dawley rat bile at 200 mg/kg administered as single oral dose after 24 hrs by HPLC method2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID462348Inhibition of mushroom tyrosinase at 100 uM2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1428433Cytotoxicity against human MDA-MB-231 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1333036Cytotoxicity against human LNCAP cells assessed as cell growth inhibition at 25 uM after 48 hrs in presence of 15 nM doxorubicin by manual cell counting2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214761Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID755105Inhibition of CYP3A4/5 in human intestinal microsomes using midazolam as substrate after 4 mins2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
AID621925Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID1333032Cytotoxicity against human LoVo cells assessed as reduction in cell growth at 50 to 200 uM after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID1214781Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg to IC50 for OATP1B3 (unknown origin) expressed in HEK293 cells2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1214765Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting in presence of OATP inhibitor BSP2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1333037Antitumor activity against humanPC3 cells xenografted in nude mouse assessed as tumor growth inhibition at 100 mg/kg, po administered via gavage for 5 days per week for 7 weeks relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214772Plasma concentration in patient with chronic noncirrhotic HCV at 420 to 700 mg administered 3 times per day2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462342Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 30 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1214778Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg to IC50 for OATP1B1 (unknown origin) expressed in HEK293 cells2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1333035Cytotoxicity against human DU145 cells assessed as cell growth inhibition at 100 uM after 48 hrs in presence of 25 nM doxorubicin by manual cell counting2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1254733Oral bioavailability in human2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Development of Safe and Effective Botanical Dietary Supplements.
AID1333030Cytotoxicity against human PC3 cells assessed as cell growth inhibition at 200 uM after 48 hrs by MTT assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214766Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting in presence of OATP inhibitor BSP2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1214775Cmax at steady state in patient with chronic HCV infection at 140 mg administered 3 times per day2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1214774Unbound fraction in human plasma2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462334Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 10 uM after 72 hrs2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1782126Cytotoxicity against human differentiated SH-SY5Y cells assessed as reduction in cell viability at 2 to 50 uM measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release.
AID462339Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 1 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1419577Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Design and discovery of silybin analogues as antiproliferative compounds using a ring disjunctive - Based, natural product lead optimization approach.
AID1214782Ratio of fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 700 mg to IC50 for OATP2B1 (unknown origin) expressed in HEK293 cells2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1333027Antiviral activity against Hepatitis C virus in liver transplanted patient with established HCV recurrence assessed as reduction in viral load at 20 mg/kg, iv administered for 14 days2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214768Inhibition of OATP-mediated [3H]estradiol-17beta-glucuronide uptake in sandwich-cultured human hepatocytes at 100 uM after 1 day by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1428430Cytotoxicity against human HepG2 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID621929Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID462359Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 30 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1333033Antitumor activity against human HT-29 cells xenografted in nude mouse assessed as tumor growth inhibition at 200 mg/kg, po administered 5 days per week for 32 days2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214769Inhibition of OATP-mediated [3H]rosuvastatin uptake in sandwich-cultured human hepatocytes at 100 uM after 1 day by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1214771Inhibition of OATP-mediated [3H]rosuvastatin uptake in sandwich-cultured human hepatocytes at 100 uM after 8 days by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1333025Inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate at after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214757Cmax in patient with chronic noncirrhotic HCV infection at 140 mg2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1428429Cytotoxicity against human PC3 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1214767Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake after 3 mins by beta-counting in presence of OATP inhibitor BSP2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1428436Cytotoxicity against human primary prostate mesenchymal cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1214759Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake at 10 uM after 3 mins by beta-counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1759236Inhibition of hyaluronic acid deposition in human LX2 cells2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis and anti-fibrotic effects of santamarin derivatives as cytotoxic agents against hepatic stellate cell line LX2.
AID462353Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 1 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1869057Activation of chymotrypsin-like activity of yeast 20s proteasome alpha3deltaN mutant using suc-LLVY-AMC as flurogenic substrate at 0.1 to 5 uM preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence assay2022Bioorganic & medicinal chemistry, 07-15, Volume: 66Silybins are stereospecific regulators of the 20S proteasome.
AID462361Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 3 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1782120Antioxidant activity assessed as DPPH radical scavenging activity measured for 60 mins by spectrophotometric analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release.
AID462367Inhibition of mushroom tyrosinase assessed as inhibition of melanin production from dopachrome by autoxidation at 100 uM2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1428435Cytotoxicity against human CAL51 at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID755108Antiviral activity against HCV JFH-1 infected in human Huh7.5.1 cells assessed as viral core protein expression at 6.2 to 62.1 uM after 72 hrs by Western blot analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
AID1214776fCmax in portal vein of patient with chronic noncirrhotic HCV infection at 140 mg2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462338Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1428428Cytotoxicity against human BJ cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1333024Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs in presence of curcumin by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID1214764Fraction absorbed in rat2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID462358Effect on TRP1 mRNA expression in mouse B16-4A5 cells assessed as TRP1 mRNA/beta-actin mRNA expression ratio at 10 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1428432Cytotoxicity against human HL60 cells at 0.0003 to 100 uM after 48 hrs by ATPlite assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Silychristin: Skeletal Alterations and Biological Activities.
AID1586111Antiviral activity against HCV JFH-1 infected in human Huh7.5.1 cells assessed as reduction in NS3/NS5A expression by Western blot analysis2018Journal of natural products, 12-28, Volume: 81, Issue:12
1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.
AID462355Effect on tyrosinase mRNA expression in mouse B16-4A5 cells assessed as tyrosinase mRNA/beta-actin mRNA expression ratio at 30 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1759238Inhibition of collagen type 1 deposition in human LX2 cells2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis and anti-fibrotic effects of santamarin derivatives as cytotoxic agents against hepatic stellate cell line LX2.
AID1726505Binding affinity to HSP90 C-terminal domain (unknown origin) by biochemical assay2021RSC medicinal chemistry, Mar-01, Volume: 12, Issue:3
Using NMR to identify binding regions for N and C-terminal Hsp90 inhibitors using Hsp90 domains.
AID1869058Activation of chymotrypsin-like activity of human 20s proteasome using suc-LLVY-AMC as flurogenic substrate at 0.1 to 5 uM preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence assay2022Bioorganic & medicinal chemistry, 07-15, Volume: 66Silybins are stereospecific regulators of the 20S proteasome.
AID1425897Competitive inhibition of GLUT4 in mouse 3T3L1 cells assessed as reduction in insulin-stimulated [3H]-2-deoxy-D-glucose uptake preincubated for 20 mins followed by measured for [3H]-2-deoxy-D-glucose addition measured after 1 to 10 mins by Lineweaver-Burk2016MedChemComm, Sep-01, Volume: 7, Issue:9
Anticancer agents interacting with membrane glucose transporters.
AID462363Effect on TRP2 mRNA expression in mouse B16-4A5 cells assessed as TRP2 mRNA/beta-actin mRNA expression ratio at 30 uM in presence of 1 mM theophylline after 72 hrs by RT-PCR2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
AID1333038Cytotoxicity against human LoVo cells assessed as reduction in cell growth after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
AID755112Cytotoxicity against human Huh7.5.1 cells after 72 hrs2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
AID1214756Cmax in patient with chronic noncirrhotic HCV infection at 700 mg2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,168)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (0.68)18.7374
1990's4 (0.34)18.2507
2000's242 (20.72)29.6817
2010's682 (58.39)24.3611
2020's232 (19.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.96 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index87.08 (26.88)
Search Engine Supply Index3.67 (0.95)

This Compound (35.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials31 (2.74%)5.53%
Reviews3 (6.12%)6.00%
Reviews2 (5.88%)6.00%
Reviews78 (6.88%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies22 (1.94%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational1 (0.09%)0.25%
Other46 (93.88%)84.16%
Other32 (94.12%)84.16%
Other1,001 (88.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Double Arm Randomized Trial for Patients With Multiple Brain Metastasis and/or Leptomeningeal Carcinomatosis: Comparison of WBRT Alone and WBRT Plus Silibinin (Sillbrain) [NCT05793489]44 participants (Anticipated)Interventional2023-03-06Recruiting
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma [NCT02146118]Phase 242 participants (Anticipated)Interventional2014-04-30Recruiting
Trial of Indole-3-Carbinol & Silibinin [NCT03687073]Phase 121 participants (Actual)Interventional2018-11-29Completed
Phase I Trial of Siliphos in Patients With Advanced Hepatocellular Carcinoma [NCT01129570]Phase 13 participants (Actual)Interventional2010-02-28Completed
Topical Silymarin Cream Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: Split Face Study [NCT04490967]Phase 430 participants (Anticipated)Interventional2021-04-30Not yet recruiting
A Phase 2 Randomized, Multicenter Trial on Silibinin To Prevent Intracranial Recurrence After Gross-Total Resection of Single Brain Metastasis From Non-Small Cell Lung Cancer or Breast Cancer [NCT05689619]70 participants (Anticipated)Interventional2023-09-01Recruiting
Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study [NCT03538327]Phase 450 participants (Actual)Interventional2013-10-31Completed
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy. [NCT00915200]Phase 2114 participants (Actual)Interventional2009-10-31Completed
Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C [NCT00684268]Phase 270 participants (Actual)Interventional2007-10-31Completed
[NCT01935817]Phase 364 participants (Actual)Interventional2010-06-30Completed
Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability [NCT01957319]Phase 372 participants (Actual)Interventional2010-02-28Completed
Open Label, Randomized, 2 Way-crossover Study to Investigate the Absolute Bioavailability of Oral Sylibin [NCT02633696]Phase 18 participants (Actual)Interventional2013-10-31Completed
A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon® SIL) for Amatoxin Induced Hepatic Failure [NCT00915681]Phase 2148 participants (Actual)Interventional2009-11-10Terminated(stopped due to Sponsor decision)
A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon® SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment [NCT01871662]Phase 2/Phase 30 participants (Actual)Interventional2013-08-31Withdrawn
Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy [NCT01265563]Phase 2108 participants (Actual)Interventional2011-01-31Completed
The Role of the PNPLA3, TM6SF2 and MBOAT7 Genetic Variants in the Response to Silybin-phospholipid Complex, Vitamin D and Vitamin E Based Therapy for Non-alcoholic Fatty Liver Disease Patients [NCT04640324]92 participants (Actual)Interventional2017-01-16Completed
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients [NCT01518933]Phase 220 participants (Actual)Interventional2011-08-31Terminated(stopped due to when a blind review highlighted that at least 43% of patients had a virological response)
A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients [NCT01535092]Phase 214 participants (Actual)Interventional2010-09-30Terminated(stopped due to when realized that the target 60% of patients with SVR was no more achievable)
A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swi [NCT01816490]Phase 220 participants (Anticipated)Interventional2013-04-30Completed
Effects of Compound Silymarin on Biomarkers of Lipid Metabolism and Inflammation in Patients With Non-alcoholic Fatty Liver Disease: A Randomized Controlled Double-blind Trial [NCT05497765]129 participants (Anticipated)Interventional2022-08-01Recruiting
Effect of Milk Thistle Derivative Silibinin(A) as a Potential Anti-obesity Agent [NCT05069298]60 participants (Anticipated)Interventional2023-01-12Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01265563 (2) [back to overview]Change From Baseline in Hemoglobin-A1c
NCT01265563 (2) [back to overview]Change From Baseline in Urinary Albumin Excretion

Change From Baseline in Hemoglobin-A1c

Hemoglobin A1C was assessed at the end of the run in period and after 3 months of administration of study interventions. Here is delta HgA1C is reported between the two periods (NCT01265563)
Timeframe: Baseline and 3 months

Interventionpercentage (Mean)
NAC Placebo + Silibin Placebo0.35
NAC Active + Silibin Placebo-0.18
NAC Placebo + Silibin Active0.72
NAC Active + Silibin Active0.4
NAC Active + High-dose Silibin Active0.2

[back to top]

Change From Baseline in Urinary Albumin Excretion

Urine albumin to creatinine ratio was assessed at the end of run in period and after 3 months administration of study intervention. (NCT01265563)
Timeframe: Baseline and 3 months

Interventionmg/g (Mean)
NAC Placebo + Silibin Placebo50.5
NAC Active + Silibin Placebo-28.13
NAC Placebo + Silibin Active-4.5
NAC Active + Silibin Active96.6
NAC Active + High-dose Silibin Active353.71

[back to top]